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ABSTRACT
One of the largest obstacles in drug development is to overcome solubility
and bioavailability problems.

Preformulation strategies such as nanoparticle

formation are often employed but sometimes create new issues and are limited in
their effectiveness and applications. Since the majority of drugs are marketed
and sold as solid forms, drug delivery systems are not always desirable. This is
where solid-state chemistry becomes important. Traditional solid-state chemistry
approaches are often successful but are sometimes too restrictive and cannot be
applied to certain compounds. Cocrystals have emerged as an alternative solidstate technique that can be applied to a broad range of compounds. However,
the technology is still very new and its effectiveness in certain conditions had
previously not been evaluated.
The studies detailed herein investigated the ability of two different
technology platforms for overcoming drug design challenges for two promising
bioflavonoids: EGCg and quercetin. Studies have shown that EGCg might be
useful for the treatment of Alzheimer’s disease and other neurodegenerative
diseases.

Quercetin is being investigated for numerous bioactivities and is

currently being marketed as an energy dietary supplement.

Both of these

bioflavonoids exhibit poor bioavailability and water solubilities that are at opposite
ends of the spectrum. In the chapters to follow, nanoparticle technology was
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applied to EGCg and evaluated in cell models of Aβ production, a hallmark of
Alzheimer’s disease. Bioavailability improvements were also evaluated in rats.
Additionally, new forms of both flavonoids were created using cocrystallization.
These new cocrystals were characterized using powder and single crystal x-ray
diffraction, differential scanning calorimetry, and thermogravimetric analysis.
Solubility and bioavailability changes were also evaluated.

These data have

strong implications in drug development since they elucidated the strengths and
weaknesses of two major technologies in compounds with different design
challenges.
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CHAPTER 1
INTRODUCTION

1.1 Bioflavonoids
Bioflavonoids are a group of polyphenolic compounds that are common
throughout the plant kingdom. They are widely studied and have been found to
promote healthy living in epidemiologic studies (Hertog 1996; Arts 2008). Much
of the attention that bioflavonoids have attracted is due mainly to the “French
paradox”.

This is the dietary anomaly in which people in the Mediterranean

culture have a higher fat intake but a lower incidence of cardiovascular disease
and increased longevity (Formica and Regelson 1995). This phenomenon has
been largely attributed to increased dietary intake in bioflavonoids.
1.2 (-)-Epigallocatechin-3-Gallate
1.2.1 EGCg Therapeutic Properties
EGCg has been studied extensively during the last decade for it’s therapeutic
potential in various cancers (Jung, Kim et al. 2001; Wang and Bachrach 2002;
Hwang, Ha et al. 2007; Lim, Park et al. 2008; Wang, Hao et al. 2009),
Alzheimer’s disease (Rezai-Zadeh, Shytle et al. 2005; Obregon, Rezai-Zadeh et
al. 2006; Rezai-Zadeh, Arendash et al. 2008; Lin, Chen et al. 2009), obesity
(Hwang, Park et al. 2005; Wolfram 2007), and diabetes (Lin and Lin 2008; Cai
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and Lin 2009). In the chapters to come the focus will be on EGCg’s potential as
an Alzheimer’s disease therapeutic. Therapies that oppose cleavage of amyloid
precursor protein (APP) into Aβ peptides and resultant cerebral amyloidosis, a
key pathological feature of Alzheimer's disease (AD), have become a primary
focus in the recent years. The main targets have been β- and γ-secretase, the
two proteases that cleave APP at the amino and carboxyl-terminus of the Aβ
peptide, respectively, and hence are directly responsible for Aβ peptide
generation. However, numerous studies have shown that γ-secretases critically
involve physiologically important signaling mechanisms required for cell-fate
decisions during development and even during adulthood (De Strooper, Annaert
et al. 1999; Walsh, Fadeeva et al. 2003). Most recently, it has been reported that
β-secretase modulates myelination in the central and peripheral nervous system
(Hu, Hicks et al. 2006).

An alternative strategy, namely the activation of α-

secretase, has scarcely been investigated for its therapeutic potential.

α-

secretase cleaves APP substrate within the Aβ peptide domain and precludes
peptide generation, thereby promoting the non-amyloidogenic pathway of APP
proteolysis. α-secretase activation may even have the added advantage of, not
only preventing neurotoxic Aβ peptide formation, but also generating the
putatively neuroprotective sAPP-α. Recently, we found that oral administration of
green tea-EGCg reduces β-amyloid mediated cognitive impairment, reduces
inflammation, and also modulates tau pathology in an Alzheimer's disease
transgenic mouse model (Rezai-Zadeh, Shytle et al. 2005; Arendash, Schleif et
al. 2006; Obregon, Rezai-Zadeh et al. 2006; Rezai-Zadeh, Arendash et al. 2008).
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For these reasons, EGCg was selected as one of the bioflavonoids for the
studies to be discussed in the chapters to come.
1.2.2 EGCg Metabolism
The metabolism of EGCg has been identified as a major factor contributing to its
low oral bioavailability. For this reason, EGCg metabolism has been studied in
mice, rats, and humans. Because rats are most commonly used for preclinical
bioavailability studies, there have been numerous studies on the absorption and
metabolism of EGCg in rats (Chen, Lee et al. 1997; Nakagawa and Miyazawa
1997). Rats are typically the preferred species for bioavailability studies because
they offer the logistical advantage of being more tolerant to the volumes of blood
that must be withdrawn in order to generate a pharmacokinetic curve for each
rat. In mice, multiple animals must be sacrificed to generate data for each time
point. However, recent data suggests that mice may metabolize polyphenols in a
manner that more closely resembles human metabolism from a mechanistic
perspective (Lu, Meng et al. 2003).

EGCg metabolism was studied in the

presence of mice, rat, and human UDP-glucuronosyl-transferase.

The

investigators reported that mice and humans had a more similar EGCg
metabolite profile than rats and humans (Lu, Meng et al. 2003).

This is

evidenced by the presence of similar levels of (-)-EGCg-4"-O-glucuronide and (-)EGCg-3"-O-glucuronide in mice and in humans.

In additional experiments,

Lambert and colleagues reported that the rat liver cytosol had a substantially
higher capacity for methylating and sulfating EGCg than mice or human liver
cytosol (Lambert, Lee et al. 2003).

This would account for the previously
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reported lower bioavailabilities reported for rats, 1.6 ± 0.6% than for mice, 26.5 ±
7.5% (Lambert, Lee et al. 2003). In mice and in humans, EGCg is reported to be
extensively glucoronidated by UDP-glucuronosyl-transferase, which is present at
high levels in the intestine and liver (Lambert, Lee et al. 2003; Lu, Meng et al.
2003). This metabolic conjugation reduces the levels of free EGCg in systemic
circulation for transport to the target organs. Because higher levels of free EGCg
have been observed in mice than in humans, it would seem that UDPglucuronosyltransferases may not be as effective at metabolizing EGCg as
sulfotransferases and methyltransferases in rats or is more easily saturated.
Nonetheless, EGCg preformulation studies where metabolism is a targeted
parameter for improving the pharmacokinetics should use a mouse model, as it is
probably most relevant for translation in humans. Recently, a clinical trial was
conducted to assess whether or not long term EGCg supplementation would
modulate the cytochrome P450 (CYP) system in man, an essential system for
drug metabolism.

They reported that EGCg had no effects on CYP1A2,

CYP2D6, and CYP2C9, but had very small effects on CYP3A4 activity (Chow,
Hakim et al. 2006). Chow and colleagues concluded that it is unlikely that long
term EGCg administration will have any clinically relevant metabolic drug
interactions for drugs metabolized by the CYP isozymes.

Because EGCg

seemed to have no effect on CYP activity, one might also conclude that these
enzymes are likely not to blame for the low bioavailability of EGCg. However,
this presumption is yet to be determined directly.
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1.2.3 EGCg Biodistribution
Many studies with animal models have shown that EGCg can prevent
carcinogenesis of the skin, lung, oral cavity, esophagus, intestine, colon, prostate
(Yang, Maliakal et al. 2002) and exert neuroprotective effects in the central
nervous system (Xie, Jiang et al. ; Lee, Bae et al. 2004; Giunta, Obregon et al.
2006; Avramovich-Tirosh, Reznichenko et al. 2007; Hou, Chen et al. 2008;
Rezai-Zadeh, Arendash et al. 2008). Therefore, one can infer that EGCg must
reach these target organs. Several groups have studied the distribution of tea
catechins following oral consumption (Chen, Lee et al. 1997; Nakagawa and
Miyazawa 1997; Lambert, Lee et al. 2003; Lin, Wang et al. 2007). Lambert et al
reported that after intravenous administration of 21.8umol/kg of EGCg in mice,
most was distributed to the lung, liver, kidney, small intestine and colon.
However, when the EGCg was given per oral dose of 163.8umol/kg, very large
quantities of EGCg could be measured in the small intestine and in the colon
(Lambert, Lee et al. 2003). This confirms that EGCg is poorly absorbed in the
small intestine and could also be due to substantial metabolic conjugation of the
EGCg that is absorbed before it reaches systemic circulation, leading to it’s rapid
elimination before being distributed to the organs. One of the newest proposed
therapeutic uses of EGCg is that it might offer some neuroprotective properties.
However, for a compound to have direct effects on the central nervous system, it
should cross the blood brain barrier. Nakagawa measured tissue distribution of
500mg/kg EGCg 60 minutes after oral administration in rats.

EGCg

concentration was highest in the small intestine (565 nmol/g) and colon (68.6
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nmol/g), but was also measured in the liver (48.3 nmol/g) and in the brain (0.5
nmol/g) (Nakagawa and Miyazawa 1997). These results indicated that although
EGCg can penetrate the blood brain barrier, it does so poorly. Lin et al proposed
that this might be due to EGCg’s bipolar functional group and the possiblility that
EGCg is largely protein-bound in the plasma and that the complex might be too
large to traverse cells or capillary membranes in the brain (Lin, Wang et al.
2007). Thus, this is an important limitation that will need to be overcome or
compensated for by substantial increases in the systemic absorption of EGCg in
order for it to be therapeutically effective in the cerebrospinal compartment.
1.3 Quercetin
Quercetin, 3,3',4',5,7-Pentahydroxyflavone, (QUE) is one of the most common
dietary flavonoids and is found throughout the plant kingdom. A typical Western
diet was estimated to provide between 0 and 30 mg of QUE per day, most of
which is consumed as tea, red wine, fruits and vegetables (Egert, Wolffram et al.
2008). This not only supports its safety for consumption by humans (albeit at a
low dose), but also provides epidemiological evidence for its beneficial effects.
1.3.1 Quercetin Therapeutic Properties
Quercetin is best known for its antioxidant activity but has numerous other
biological

and

pharmacological

effects

including

metal

chelation,

anti-

carcinogenic, cardioprotective, bacteriostatic, and antiviral activity (Vargas and
Burd ; Bakay, Mucsi et al. 1968; Formica and Regelson 1995; Spencer, Kuhnle
et al. 2003; Leopoldini, Russo et al. 2006; Murakami, Ashida et al. 2008).
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1.4 Lipid Carriers
Self-assembled polymer micelles based on amphiphilic block copolymers have
attracted substantial interest as delivery vehicles particularly for anti-cancer
drugs (Yokoyama, Fukushima et al. 1998; Bontha, Kabanov et al. 2006; Liu, Lee
et al. 2006; Tian, Bromberg et al. 2007; Huynh, Passirani et al. 2009; Kim,
Kabanov et al. 2009; Siddiqui, Adhami et al. 2009). Additionally, lipid carriers
with incorporated drugs have been demonstrated to increase the absorption and
circulation time in the body versus stand-alone compounds secondary to
minimized renal clearance (Maeda 2001; Huynh, Passirani et al. 2009).
Liposomes have been shown to increase the permeability of tea catechins,
including EGCg, in a mouse model of basal cell carcinoma (Fang, Lee et al.
2006). However, this study involved intratumor injection and, therefore, did not
address the issue of oral bioavailability.
1.5 Cocrystals
Formulation of pharmaceutical ingredients is a fundamental process in drug
development.

Isolation of crystal forms of active pharmaceutical ingredients

(API) is paramount in the industry in order to obtain pure forms. However, in
many cases the crystalline API has less than favorable physicochemical
characteristics.

For this reason, a new branch of formulation is growing in

popularity, crystal engineering. Crystal engineering can be used to create new
multi-component crystalline solids coined cocrystals. Shan and Zaworotko have
defined cocrystals as “multiple component crystals in which all components are
solid under ambient conditions. These components co-exist as a stoichiometric
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ratio of a target molecule or ion and a neutral molecular cocrystal former(s)”
(Shan and Zaworotko 2008). Cocrystals are of growing interest because often
various cocrystals can be formed that improve the physicochemical properties
(e.g. solubility and stability), improve efficacy (e.g. bioavailability), and provide
means for extending the life cycle of old APIs (Yadav, Shete et al. 2009). In a
recent study, cocrystallization was used to improve the dissolution profile of a
Class II BCS compound (low solubility, high permeability) such that it’s water
solubility was 18 times greater, which translated into plasma concentration
values that were three fold higher in dogs following oral administration
(McNamara, Childs et al. 2006).

These findings lend promise to the use of

cocrystallization for improving APIs and could even prevent potentially useful
compounds from being ignored due to poor clinical efficacy.
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CHAPTER 2
MATERIALS AND METHODS

2.1 Reagents and Materials
Green tea-derived EGCg (>95% purity by HPLC) was purchased from
www.herbs-tech.com. Quercetin dihydrate (98% purity), Isonicotinamide (INM)
(99% purity), Caffeine (CAF), and Theobromine (TBR) (98% purity) were
purchased from Sigma-Aldrich Corporation (St. Louis, MO, USA).

The BCA

protein assay kit was purchased from Pierce Biotechnology (Rockford, IL, USA).
Anti-human amyloid-βჼantibodies 4G8 and 6E10 were obtained from Signet
Laboratories (Dedham, MA, USA) and Biosource International (Camarillo, CA,
USA), respectively.
2.2 Cell Models
2.2.1 SweAPP N2a cells; APP695
Murine neuroblastoma cells (N2a) stably transfected with the “Swedish” mutant
form of APP (SweAPP N2a Cells; APP695), a well-established model for
mimicking Aβ overproduction characteristic of Alzhiemer’s disease were kind gifts
from S. Gandy (Thomas Jefferson University, Philadelphia, PA, USA). These
cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM), 10%
fetal calf serum (FCS), and 200 µg/ml G418 (for selection). Prior to treatment
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N2a cells were differentiated in serum-free Neurobasal medium supplemented
with 300 µM dibutyryl-cAMP for 4 hours.
2.3 Sample Processing/ELISA
2.3.1 Lysate preparation
All cultured cells were lysed in ice-cold lysis buffer (20 mM Tris, pH 7.5, 150 mM
NaCl, 1 mM EDTA, 1 mM EGTA, 1% v/v Triton X-100, 2.5 mM sodium
pyrophosphate, 1 mM β-glycerolphosphate, 1 mM Na3VO4, 1 µg/mL leupeptin, 1
mM PMSF) for 5 minutes followed by scraping. Lysates were collected and
centrifuged at 14,000 x g for 15 minutes at 4°C. Protein levels in cell lysate
supernatants were determined and normalized by bicinchoninic acid assay (BCA;
Pierce Biotechnology, Rockford, IL, USA) in accordance with the manufacturer’s
instruction.
2.3.2 Aβ ELISA
Conditioned media was collected and total Aβ1-40,42 species were quantified as
previously described (Tan et al., 2002).

Briefly, 96-well immunoassay plates

were coated with monoclonal anti-Aβ1-17 antibody (6E10; 2 µg/mL in PBS;
Signet Laboratories, Dedham, MA, USA) overnight at 4 °C. Plates were washed
with 0.05% Tween 20 in PBS 5 times and incubated with blocking buffer (PBS
with 1% bovine serum albumin (BSA), 5% horse serum) for 2 hours at room
temperature.

Conditioned media and standards were added to the plates,

following appropriate dilutions, and incubated overnight at 4 °C. Following 3
washes, biotinylated anti-Aβ17–26 monoclonal antibody (4G8; 0.5 µg/mL in PBS
with 1% BSA; Signet Laboratories) was added to the plates and incubated for 2
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hours at room temperature. After 5 washes, streptavidin-horseradish peroxidase
(HRP) (1:200 diluted in PBS with 1% BSA) was added to the 96-well plates for 30
minutes at room temperature. Tetramethylbenzidine (TMB) substrate was added
to the plates and incubated for 15 minutes at room temperature. Stop solution
(2N H2SO4) was added to stop the colorimetric reaction and optical density was
determined immediately by a microplate reader at 450 nm. ELISA values from
were reported as % change from control or pg of Aβ/mg of total protein, as
determined by BCA assay.
2.3.3 sAPP-α ELISA
Conditioned media was collected and sAPP-α levels were quantified using an
sAPP-α sandwich ELISA protocol as previously described (Bailey, Giunta et al.
2008).

High binding 96-well plates (Nunc, Denmark) were coated with

monoclonal antibody 22C11 diluted in 100 µL (1 µg/mL) of carbonate buffer (pH
9.6) and incubated overnight at 4°C. The plate was washed five times with PBSTween buffer (0.05% Tween 20) and blocked with 300 µL of blocking buffer (1%
BSA, 5% Horse Serum in PBS) for 2 hrs at 37°C. Synthetic sAPP-α protein
(Abgent, San Diego, CA) was used as the positive control for this ELISA. All
samples were analyzed in duplicate. 100 µL samples of conditioned media were
added to each well of the plate. The plate was incubated for 2 hrs at 37°C. After
washing 5 times, 100 µL of goat anti-human antibody 6E10 (Biosource; diluted
1:3,000 in reagent diluent) was added to each well of the plate. Following 2
hour-incubation at 37°C and 5-time washing, 100 µL of anti-goat IgG conjugated
with HRP (1:1500) was added to each well of the plate. The plate was incubated
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for 1 hour at 37°C. Following 5-time washing, 100 µL of substrate solution (TMB)
was added to each well and plate was incubated at room temperature. Twenty
minutes later, 50 µL of stop solution (2 N H2SO4) was added to each well of the
plate. The optical density was determined using a microplate reader at 450 nm.
Total intracellular protein was quantified using a BCA kit (Pierce Biotechnology,
Rockford, IL) in accordance with the manufacturer's instructions.

Data was

reported as ng of sAPP-α/mg of total intracellular protein produced per well.
2.4 Syntheses
2.4.1 NanoEGCg synthesis
Nanolipidic particles (NanoEGCg) are prepared using a proprietary (US
Provisional Patent Application #61/238,381) co-solubilization methodology
involving use of monophasic liquid preparations developed by Nature’s Defense
Systems, Tampa, Florida. These particles have a defined size range from 30 to
80nm. To form NanoEGCg co-solubilization methodology involving use of
monophasic liquid preparations will be employed with proprietary starting
materials. These materials are first solubilized into a water-in-ethanol solution
(Step 1).

Anhydrous EGCg was added to the materials in Step 1 and co-

solubilized by mixing at room temperature (Step 2). NanoEGCg particles were
formed by the addition of distilled water while mixing materials (Step 3). The final
preparation of NanoEGCg particles was stirred for an additional 10 minutes prior
to subjecting the preparation to sizing analysis with a Wyatt DynaPro Multiwell
Reader (Wyatt Technology Corporation, Santa Barbara, California). The stock
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formulations were stored at 20˚C and protected from light until needed for no
longer than 3 weeks to ensure integrity.
2.4.2 Bulk cocrystal synthesis
The cocrystals were made in bulk for dissolution study by slurry method. For
each cocrystal stoichiometric amounts of the starting materials in 5-6 mL of
ethanol and stirred overnight with the help of a magnetic stir bar on a stir plate,
which produces the cocrystals with 100% yield. The purity of the bulk material is
tested by powder X-ray diffraction (PXRD) and differential scanning calorimetry
(DSC). For PXRD pattern of the bulk material is compared to the PXRD obtained
from the single crystal X-ray diffraction and presence of any additional peaks
other than the peaks in the calculated pattern indicates starting materials or
impurities. Likewise, the DSC of the bulk cocrystal exhibits endotherm for the
melting point of the cocrystals and the desolvation/dehydration.
2.5 Cocrystal characterization
2.5.1 Differential scanning calorimetry (DSC)
Thermal analysis was performed on a TA Instruments DSC 2920 Differential
Scanning Calorimeter.

Aluminum pans were used for all samples and the

instrument was calibrated using an indium standard. For reference, an empty
pan sealed in the same way as the sample was used. Using inert nitrogen
conditions, the samples were heated in the DSC cell from 30 °C to the required
temperature (melting point of the cocrystal) at a rate of 10 °C/min.
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2.5.2 Powder x-ray diffraction (PXRD)
A Bruker AXS D8 powder diffractometer was used for all PXRD measurements
with experimental parameters as follows: Cu Kα radiation (λ = 1.54056 Ǻ); 40 kV
and 30 mA. Scanning interval: 3–40° 2θ; time per step: 0.5 sec.

The

experimental PXRD patterns and calculated PXRD patterns from single crystal
structures were compared to confirm the composition of bulk materials.
2.5.3 Single crystal x-ray data collection and structure determinations
Crystals suitable for X-ray crystallography were selected using an optical
microscope. Single crystal X-ray diffraction data were collected and analyzed on
a Bruker-AXS SMART-APEX CCD diffractometer with monochromatized Mo Kα
radiation (λ = 0.71073 Å) connected to a KRYO-FLEX low temperature device.
2.5.4 Cocrystal water solubility
Each of the cocrystals was synthesized in bulk by taking stoichiometric ratios of
the starting materials in methanol and slurrying them for 24 hours, which
produced the cocrystals in 100% yield.

The slurries were dried at room

temperature and were sieved to attain a particle size between 53 and75 µm. The
solubility study was done by taking approximately 4 grams of the cocrystal in 30
mL of water and was stirred with magnetic stir bar at ca. 125 rmp for 24 hours.
Aliquots were drawn from the slurry and filtered using a 0.45 µm nylon filters.
The remaining solid was analyzed by PXRD and DSC and determined to be the
cocrystal and not just a mixture of the starting materials. For every cocrystal,
1mL of the filtered solution from the slurry was transferred into a pre-weighed
(w1) vial by using an analytical balance and was put on a hot plate (maintained at

	
  

14	
  

	
  

50 oC) to evaporate the water.

The vial was weighed again (w2) and the

difference in the weights (w2-w1) gave the weight of the cocrystal in 1ml of water
from which the weight of the API was calculated. The solubility studies and the
gravimetric methods were done in replicates of three. Since the solubility of
quercetin dihydrate is so low, it was impossible to obtain experimentally using our
gravimetric method. Therefore, we used the reported solubility from the literature
for comparison (Srinivas, King et al. 2010).
2.6 Intragastric gavage
All animals were food (not water) deprived for 18 hours prior to the start of the
experiment. All formulations were delivered to the animals via oral gavage. The
dosage used for all APIs was 100 mg/kg.
2.7 Chromatography
2.7.1 EGCg liquid chromatography with tandem mass spectroscopy
To accurately quantify the concentration of EGCg in the plasma, a previously
described method was employed using liquid chromatography with tandem mass
spectrometry (Wang, Hop et al. 2000; Sparidans, Lagas et al. 2007; Wang and
Miksa 2007).
Stock preparation
A 2.00 mg/mL stock solution of EGCg in DMSO was prepared. The standard
spiking solutions were prepared by diluting the stock solution to 1000 and 100
µg/mL using acetonitrile:water (1:1, v:v). Both solutions were protected from light
using amber vials and all solutions were stored at −20 ◦C.
Standard curve preparation
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For this analysis two standard curves were prepared one with a higher (10–0.100
µg/ml) dynamic range the other a lower (1000–10ng/ml). Both standard curves
were prepared using the appropriate blank plasma containing the preservative.
The results indicated that the standard curve performance was within acceptable
range for bioanalytical method acceptance (R2>0.99) (Sparidans et al., 2007;
Wang and Miksa, 2007; Wang et al., 2000).
2.7.2 Quercetin liquid chromatography with tandem mass spectroscopy
The plasma samples were analyzed for QUE content by the Burnham Institute for
Medical Research Pharmacology Core (Orlando, FL). To accurately quantify the
concentration of QUE in the plasma, a previously described method was
employed using liquid chromatography with tandem mass spectrometry (Wang
and Morris 2005). The standards were prepared as follows. A 2.00 mg/mL stock
solution of QUE was accurately prepared in DMSO. The stock solution was
protected from light using amber vials and stored at -20°C. Standards were
prepared using the appropriate blank rat plasma with the ascorbic acid and
EDTA preservative.

The samples were aliquotted into pre-labeled 1.7 mL

microcentrifuge tubes. 100 µL was used as the aliquot volume for all samples.
Except for the double blanks, 400 µL of the internal standard spiking solution
(Naproxen, 2.00 µg/mL in ACN) was added to all samples. Tubes were then
capped, vortexed for 3 minutes and centrifuged for 10 minutes at 14,000 rpm.
Approximately 300 µL was then transferred from each tube into a 96-well plate
for analysis by LCMSMS. The concentration range of the standard curve was 10
µg/mL to 0.100 µg/mL of QUE. The results indicated that the standard curve
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performance was within acceptable range for bioanalytical method acceptance
(R2> 0.99) (Wang, Hop et al. 2000; Sparidans, Lagas et al. 2007; Wang and
Miksa 2007).
2.8 Pharmacokinetic parameter calculations
Mean plasma EGCg concentrations ± the standard error in the mean (SEM) was
calculated using GraphPad PRISM software (GraphPad Software, Inc.).
Pharmacokinetic graphs and parameters were determined using GraphPad
PRISM. Pharmacokinetic parameters included Cmax, Tmax, T1/2, area under curve
(AUC), and relative bioavailiblity (Frel). Relative bioavailibility was determined by
dividing the AUC of each NanoEGCg formulation by the AUC of the control.
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CHAPTER 3

NANOLIPIDIC PARTICLES IMPROVE THE BIOAVAILABILITY AND ALPHASECRETASE INDUCING ABILITY OF EPIGALLOCATECHIN-3-GALLATE
(EGCg) FOR THE TREATMENT OF ALZHEIMER'S DISEASE

3.1 Introduction
The deterioration, malfunction, or death of neurons is a common
etiological factor in several diseases including Alzheimer’s Disease (AD) and
HIV-associated dementia (HAD) (Wojtera, Sikorska et al. 2005; Alisky 2007). As
the

number

of

elderly

individuals

continues

to

rapidly

increase,

neurodegenerative disease, marked by progressive loss of mnemonic and higher
cortical functions, has led to a massive socioeconomic burden which is projected
to worsen (Tarkowski, Liljeroth et al. 2003).

Specifically, some 15% of the

population greater than 65 years of age suffers from dementia (Meeuwsen,
German et al. 2009).

Its presentation is heterogeneous as it is caused by

multiple disorders. Alzheimer’s disease (AD) and vascular dementia (VaD) are
the two main causes of dementia affecting between 25–45% and 15–35%,
respectively, of all patients suffering from dementia (Burns and Iliffe 2009).
Among dementias where brain infectious viruses are etiologic, human
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immunodeficiency virus type 1 (HIV-1) associated dementia (HAD) is the most
common cause of dementia (Ghafouri, Amini et al. 2006).

Prevention of

amyloidogenic processing of amyloid precursor protein with the use of natural
phytochemicals capable of enhancing α-secretase activity may be a therapeutic
approach for treatment of neurodegenerative diseases including Alzheimer’s
disease (AD) and HIV-associated dementia (HAD). We have previously shown
that modulation of apoptosis cascades (Giunta, Obregon et al. 2006; Giunta,
Zhou et al. 2008), and APP (amyloid precursor protein) processing (RezaiZadeh, Shytle et al. 2005; Obregon, Rezai-Zadeh et al. 2006; Rezai-Zadeh,
Shytle et al. 2008) with the green tea polyphenol, (-)-epigallocatechin-3-gallate
(EGCg) is a plausible therapy in mouse models of AD and HAD. In spite of these
preclinical works, translating them to a human clinical trial has presented
problems, primarily as a result of inefficient systemic delivery and bioavailability
issues.

To achieve maximum response of a neuroprotective agent, novel

strategies are required to enhance the oral bioavailability of potentially useful
agents.

Self-assembled polymer micelles based on amphiphilic block

copolymers have attracted substantial interest as delivery vehicles particularly for
anti-cancer drugs (Yokoyama, Fukushima et al. 1998; Bontha, Kabanov et al.
2006; Liu, Lee et al. 2006; Tian, Bromberg et al. 2007; Huynh, Passirani et al.
2009; Kim, Kabanov et al. 2009; Siddiqui, Adhami et al. 2009). Additionally, lipid
carriers with incorporated drugs have been demonstrated to increase the
absorption and circulation time in the body versus stand-alone compounds
secondary to minimized renal clearance (Maeda 2001; Huynh, Passirani et al.
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2009). This study investigated the ability of nanolipidic particle complexes for
increasing the oral bioavailability of EGCg. These nanoparticles (NanoEGCg)
differ from traditional liposomes because they do not require micelle formation.
Rather, they are drug:lipid complexes. This enables the formation of smaller
diameter particles that we hypothesized would be useful for increasing the oral
bioavailability of EGCg.
3.2 Materials and Methods
3.2.1 Reagents
Green tea-derived EGCg (>95% purity by HPLC) was purchased from
www.herbs-tech.com. The BCA protein assay kit was purchased from Pierce
Biotechnology (Rockford, IL, USA). Anti-human amyloid-β antibodies 4G8 and
6E10 were obtained from Signet Laboratories (Dedham, MA, USA) and
Biosource International (Camarillo, CA, USA), respectively.
3.2.2 Preparation of Nanolipidic EGCg Particles (NanoEGCg)
NanoEGCg was prepared as described in 2.4.1. Six nanoparticle formulations
were prepared for the study with various ratios of lipid carrier to EGCg.
Formulations prepared for this study were 1:1, 1:2, 1:4, 1:8, 1:16, 1:32
(Nanocarrier material to EGCg on a mg/mg basis).

Each formulation was

subjected to sizing analysis using a Wyatt DynaPro Multiwell Reader (Wyatt
Technology Corporation, Santa Barbara, California). This data is presented in
figure 3.1. The particle size was found to range from 30 to 80 nm.
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Figure 3.1
Dynamic light scattering data. A Wyatt DynaPro Multiwell Reader was used to
characterize the diameter of the NanoEGCg particles. The data indicates a
narrow size distribution, with a cumulants mean of 49.5nm and polydispersity of
0.052.
3.2.3 Rats
Male Sprague Dawley rats weighing 200–250 g were purchased from
Harlan Laboratories (Indianapolis, IN). The rats were pre-cannulated by Harlan.
The rounded tip catheters were surgically implanted into the jugular vein of the
rats making multiple, precise blood draws painless to the animal. The rats were
food (not water) deprived for 18 h prior to the start of the experiment. The EGCg
formulations were delivered via oral gavage at a dosage of 100 mg EGCg/kg
body weight (n=3 per group; 9 total). Blood was collected at the following time
points: 0, 5, 10, 30, 60, 120, 240, and 480 min. Because heparin was kept in the
catheter lines to prevent clotting, a small amount of blood was drawn and
discarded before collecting each sample. Approximately 300ჼμL of blood was
collected in EDTA tubes for each time point. The samples were kept on ice to
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preserve their integrity, then centrifuged at 4000 rpm for 10 min, after which the
plasma was transferred to sterile centrifuge tubes. A preservative solution was
added to each plasma sample at 10% (v/v) concentration to ensure the integrity
of the EGCg during storage (Lambert, Lee et al. 2006). This preservative was
comprised of 20% ascorbic acid (to prevent oxidation of EGCg) and 0.1% EDTA
(to scavenge any metal contaminants). The samples were stored at −80 ◦C until
they were analyzed for EGCg content via LC-MSMS. The LC-MSMS method is
described in 2.7.1.
3.2.4 Bioactivity assessment of NanoEGCg formulations
Murine neuroblastoma cells that were stably transfected with the human APP
gene (APP; SweAPP N2a cells) were cultured in 24-well tissue-culture plates at 1
x 105 cells/well (n = 2 for each condition) with 0.5 mL of complete medium (MEM
medium with 10% fetal calf serum). Prior to treatment, the MEM was aspirated
and replaced with 0.5 mL of neurobasal media and differentiated with cAMP for 4
hours. Following differentiation, the cells were treated with various nanoparticle
formulations and controls (25µM - 3µM) for 18 hours. Controls included two
formulations of EGCg without a lipid carrier: one dissolved in water and another
in ethanol and water at the same ratio that the nanoparticles were formed (2.4.1).
The conditioned media was collected and sAPP-α levels were quantified using a
sAPP-α sandwich ELISA protocol as described in 2.3.3.
3.2.5 Pharmacokinetic screening of EGCg formulations in rats
Male Sprague Dawley rats weighing 200-250 g were purchased from Harlan
Laboratories (Indianapolis, IN). The rats were pre-cannulated by Harlan. The
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rounded tip catheters were surgically implanted into the jugular vein of the rats
making multiple, precise blood draws painless to the animal. The rats were food
(not water) deprived for 18 hours prior to the start of the experiment. The EGCg
formulations were delivered via oral gavage at a dosage of 100 mg EGCg/kg
body weight. Blood was collected at the following time points: 0, 5, 10, 30, 60,
120, 240, and 480 minutes. Because heparin was kept in the catheter lines to
prevent clotting, a small amount of blood was drawn and discarded before
collecting each sample. Approximately 300 µL of blood was collected in EDTA
tubes for each time point.

The samples were kept on ice to preserve their

integrity, then centrifuged at 4000 rpm for 10 minutes, after which the plasma
was transferred to sterile centrifuge tubes. A preservative solution was added to
each plasma sample at 10% (v/v) concentration to ensure the integrity of the
EGCg during storage (Lambert, Lee et al. 2006).

This preservative was

comprised of 20% ascorbic acid (to prevent oxidation of EGCg) and 0.1% EDTA
(to scavenge any metal contaminants). The samples were stored at -80°C until
they were analyzed for EGCg content.
3.2.6 Quantification of EGCg in Rat Plasma
The plasma samples were blinded and sent to be analyzed for EGCg content by
the Burnham Institute for Medical Research Pharmacology Core (Orlando, FL).
The LC-MSMS method described in 2.7.1 was utilized.
3.2.7 Pharmacokinetic Calculations
Mean plasma EGCg concentrations ± the standard error in the mean (SEM) were
calculated using GraphPad PRISM software (GraphPad Software, Inc.).
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Pharmacokinetic graphs and parameters were determined using GraphPad
PRISM.

Pharmacokinetic parameters included Cmax, Tmax, area under curve

(AUC), and relative bioavailiblity.

Relative bioavailibility was determined by

dividing the AUC of each NanoEGCg formulation by the AUC of the control.
3.2.8 Statistical Analysis
sAPP-α ELISA
A Two-way ANOVA was performed using GraphPad PRISM software (GraphPad
Software, Inc.).

This was followed by Bonferonni post-tests to assess the

significance of each NanoEGCg formulation versus the EGCg/10%EtOH/H2O
Control at each concentration.
Pharmacokinetics
A Two-way ANOVA was performed using GraphPad PRISM software (GraphPad
Software, Inc.).

This was followed by Bonferonni post-tests to assess the

significance of the 1:16 NanoEGCg formulation versus the EGCg/10%EtOH/H2O
Control at each time point.
3.3 Results
3.3.1 Encapsulating EGCg increases sAPP-α generation in cultured
SweAPP N2a cells
We utilized an in vitro model for Alzheimer’s disease to test the hypothesis that
formation of nanoparticle complexes would increase the bioactivity of EGCg by
promoting α-secretase activity in cultured SweAPP N2a cells.

These cells

overproduce human APP, making them ideal for screening compounds that
modulate APP processing (Obregon, Rezai-Zadeh et al. 2006). Additionally, we
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used this assay as a criterion to select the most effective nanoparticle
formulations to carry through to the pharmacokinetic pilot study.

Figure 3.2

shows the mean ng of sAPP-α per mg of total protein produced ± standard
deviation for all EGCg formulations. Because ethanol was used to solubilize the
lipid carrier and EGCg during the NanoEGCg productions process, it was
appropriate to include a similarly formulated EGCg solution (10% EtOH solution
v/v) to rule out any potential gains in α secretase activity being due to the alcohol
content of the nanoparticle formulations.
From figure 3.2, not all NanoEGCg formulations were effective. In fact, the 1:1
and 1:2 formulations were outperformed by the EGCg and 10%EtOH/H2O
control at all concentrations tested. The 1:8 and 1:16 NanoEGCg formulations
were selected to be advanced to the pharmacokinetics phase of the study
because they outperformed the control at all concentrations tested.

The 1:8

formulation was statistically significant at all concentrations, whereas the 1:16
was only statistically significant at the lower two concentrations. Not only did
these formulations show marked increases in sAPP-α generation but, perhaps
more importantly, they continued to promote enhanced levels of α secretase
activity even at the lowest EGCg concentration tested.
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Figure 3.2
Estimated sAPP-α generation for each treatment group.
The sAPP-α
concentration (ng/ml) was normalized to the total protein content (mg/ml). Data
is presented as mean ng of sAPP-α per mg of total protein produced ± standard
deviation. The 1:8 and 1:16 formulations were superior to the other formulations,
with the 1:8 showing 92% improvement in α secretase activity over the EtOH
control at the 3µM concentration.
The 1:8 NanoEGCg formulation was
statistically higher than the control at all concentrations tested. The 1:16
NanoEGCg formulation was statistically higher at the lower two concentrations
(*** P<.001, **P<.01, *P<.05).
3.3.2 Encapsulation improves the bioavailability of EGCg in rats
There have been numerous groups to report the poor oral bioavailability of EGCg
(Cai, Anavy et al. 2002; Lambert, Hong et al. 2004; Zhang, Zheng et al. 2004;
Feng 2006; Lambert, Sang et al. 2006; Chan, Zhang et al. 2007; Lin, Wang et al.
2007; Henning, Choo et al. 2008). Recent reports suggest that this poor oral
bioavailability is mostly due to factors such as poor absorption and intestinal
metabolism, rather than elimination via first pass metabolism (Cai, Anavy et al.
2002). Larger lipid-based bilayer delivery systems have been shown to increase
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the absorption of poorly permeable compounds (Allen 1998). This preliminary
study evaluated the ability of proprietary lipid nanoparticle complexes to increase
the oral bioavailability of EGCg in rats. Our results indicate that nanoparticles
are highly effective at increasing the absorption of EGCg into systemic
circulation. Figure 3.3 shows a compilation of the mean pharmacokinetic curves
for the nanoparticle formulation tested and the control. Because EGCg is poorly
water soluble, 10% EtOH was added to fully solubilize the EGCg at a
concentration equivalent to the NanoEGCg stock (50mg/ml) and ensure accurate
dosing in the control. Our data suggests that the nanoparticle formulations result
in substantial increases in the absorption of EGCg. Although Figure 3.3 indicates
only one NanoEGCg curve, both 1:8 and 1:16 formulations were tested.
However, both nanoparticle formulations were similarly absorbed and not
statistically different, so the 1:16 preperation was selected to represent the
NanoEGCg pharmacokinetic curve. The control was very poorly absorbed in
comparison to the NanoEGCg. Statistical significance (**P<.01) was observed at
the 5 and 10-minute time points.

Table 3.1 shows some important

pharmacokinetic parameters: Cmax, Tmax, AUC, and relative bioavailiblity. The
relative bioavailability (defined by the AUC) of the NanoEGCg was 2.31 and 2.50
for the 1:16 and 1:8 formulations, respectively, in comparison to the free EGCg in
10%EtOH solution (10%EtOH Control).
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Figure 3.3
EGCg pharmacokinetic curve (mean plasma concentration ± SEM vs. time) for
the 1:16 NanoEGCg formulation (n=3) and free EGCg in 10%EtOH solution
(n=3). The nanoparticle formulation resulted in substantial increase in systemic
EGCg absorption. Statistical significance (**P<.01) was observed at the 5 and
10-minute time points. The 10% EtOH control had very poor absorption, with
plasma concentration peaking at 116.57 ng/ml. In comparison, the 1:16
NanoEGCg reached a maximum plasma concentration of 599.33 ng/ml.

Treatment
EGCg+10% EtOH
(Control)
NanoEGCg (1:16)
NanoEGCg (1:8)

Table 3.1 Pharmacokinetic Parameters
AUC
Cmax
Tmax
(0-240min)
116.57
599.33
704.67

5
10
5

14621
33722
36524

Relative
Bioavailability
1
2.31
2.50

3.4 Discussion and Conclusion
Nanoparticles and larger liposomes have been investigated extensively for
increasing the oral bioavailability of poorly absorbed compounds (Pandey,
Ahmad et al. 2005; He, Horn et al. 2007; Kumar, Chandrasekar et al. 2007;
Frezard, Martins et al. 2008; Rao, Yajurvedi et al. 2008). It has been recently
reported that encapsulating EGCg into liposomes can improve its anti-cancer
efficacy (Siddiqui, Adhami et al. 2009) and antioxidant capacity (Italia, Datta et al.
2008), probably by increasing its bioavailability. However, these studies utilized
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larger diameter particles (>100nm) and focused primarily on improved efficacy of
EGCg for specific disease modifying parameters.

Here, we have tested the

ability of small diameter nanolipidic particle formation as a method for increasing
not only the α-secretase inducing ability of EGCg, but also its oral bioavailability.
It has been shown that an oral dose of 800mg/70kg/day provides
approximately 400ng/ml EGCg in human plasma (Chow, Cai et al. 2001). Given
that we have recently shown that 1000 - 2000ng/mL of free EGCg is necessary
for promoting APP α-secretase cleavage in SweAPP N2a cells (Rezai-Zadeh,
Shytle et al. 2005), using linear approximation, an oral dose of EGCg of
1800mg/70kg/day would be required to reach therapeutically effective plasma
concentrations of EGCg. From a safety and practicality point of view, this dose
might be unacceptable for clinical trials (Ullmann, Haller et al. 2003; Ullmann,
Haller et al. 2004). Since the oral EGCg dosage in most clinical trials for cancer
therapy is typically not more than 800 mg/day (Chow, Cai et al. 2001) regimens
which enhance EGCg bioavailability, effecting reductions in neuropathology and
cognitive decline at minimum doses, are very desirable. Thus, the bioavailability
of EGCg is an important issue for oral administration of EGCg to clinical trials.
It has been previously reported that decreased bioavailability of EGCg is
greatly associated with the glucuronidated form, which is largely present in the
plasma of treated mice (Lambert, Lee et al. 2003). Additionally, it has been
shown that piperine, an alkaloid derived from black pepper, enhances the
bioavailability of EGCg by inhibiting glucuronidation (Lambert, Hong et al. 2004).
Unfortunately the consumption of piperine also influences the metabolism of all
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other ingested food and drugs (Khajuria, Thusu et al. 2002). For example it
increases the plasma concentration of phenytoin (Pattanaik, Hota et al. 2006),
propanalol, and theophylline in healthy volunteers (Bano, Raina et al. 1991) and
plasma concentrations of rifamipicin (rifampin™) in patients with pulmonary
tuberculosis (Zutshi, Singh et al. 1985). By forming EGCg nanolipidic complexes
as we have, it is possible to increase the oral bioavailability of EGCg as well as
its AD and HAD preventative and therapeutic actions, without affecting the
absorption of other ingested compounds. This may be an important factor to
consider when bringing an EGCg therapeutic into the clinical setting.
In this study, we have modified EGCg such that it requires no coadministration of other drugs. Rather, it is co-solubilized with a lipid carrier using
proprietary methodology to form 30-80nm diameter nanoparticle complexes. The
importance of particle diameter for drug delivery is particularly important for
delivery of drugs to the brain (Wissing, Kayser et al. 2004). Previously, even
smaller diameter liposomes (100nm) have had trouble penetrating the tight
junctions between the endothelial cells of the blood brain barrier without osmotic
disruption (Sakamoto and Ido 1993).

This highlights an important distinction

between this nanoparticle technology and previous liposomal technologies, which
require micelle formation. NanoEGCg does not involve encapsulating the EGCg
into a micelle. Instead, lipid:EGCg complexes are formed. Because the EGCg is
not fully encased in a micelle structure, it is possible to achieve smaller diameter
particles without compromising the stability of the carrier.

Although this

preliminary study has demonstrated the ability of nanoparticles to increase the
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systemic absorption of EGCg taken orally, it is likely that the small diameter of
these particles will also lead to improved blood brain barrier penetration. Further
studies will be performed to investigate the possibility that nanolipidic particles
can be used to enhance the delivery of poorly absorbed drugs to the brain.
This study provides important preliminary evidence that nanolipidic
particles might be useful for safely translating EGCg into human clinical trials.
Not only did NanoEGCg more than double the oral bioavailability of EGCg in rats
(Figure 3.3) but also was more effective at promoting α-secretase activity in vitro,
even at reduced concentrations (Figure 3.2). Taken together, it is possible that
NanoEGCg will be therapeutically effective at doses that would be considered
acceptable in the clinical setting.
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CHAPTER 4

COCRYSTALS OF QUERCETIN WITH IMPROVED SOLUBILITY AND ORAL
BIOAVAILABILITY

4.1 Introduction
Flavonoids in general are widely studied and have been found to promote
healthy living in epidemiologic studies (Hertog 1996; Arts 2008).

Quercetin,

3,3',4',5,7-Pentahydroxyflavone, (QUE) is one of the most common dietary
flavonoids and is found throughout the plant kingdom (Figure 1).

A typical

Western diet was estimated to provide between 0 and 30 mg of QUE per day,
most of which is consumed as tea, red wine, fruits and vegetables (Egert,
Wolffram et al. 2008).

This not only supports its safety for consumption by

humans (albeit at a low dose), but also provides epidemiological evidence for its
beneficial effects. QUE is perhaps best known for its antioxidant activity but has
numerous other biological and pharmacological effects including metal chelation,
anti-carcinogenic, cardioprotective, bacteriostatic, and antiviral activity (Vargas
and Burd ; Bakay, Mucsi et al. 1968; Formica and Regelson 1995; Spencer,
Kuhnle et al. 2003; Leopoldini, Russo et al. 2006; Murakami, Ashida et al. 2008).
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Even though QUE has been found to have many potential beneficial
effects,

its

usefulness

in

vivo

is

questionable

due

to

unfavorable

pharmacokinetics in its pure form. The bioavailability of QUE has been studied
extensively (Hollman, van Trijp et al. 1997; Manach, Morand et al. 1997; Graefe,
Derendorf et al. 1999; Manach, Texier et al. 1999; Ader, Wessmann et al. 2000;
Graefe, Wittig et al. 2001; Cermak, Landgraf et al. 2003; Lesser, Cermak et al.
2004; Erlund, Freese et al. 2006).

Unfortunately, it appears that QUE is

absorbed poorly, is highly susceptible to metabolic conjugation, and exists mostly
as a conjugated form in systemic circulation, resulting in low bioavailability
(Manach, Texier et al. 1999; Ader, Wessmann et al. 2000). Furthermore, QUE
bioavailability has been evaluated in humans following a single 4 g oral dose.
The investigators reported that following oral administration, no measurable
plasma or urine QUE concentrations could be detected (Gugler, Leschik et al.
1975). They concluded that less than 1% of the QUE was absorbed unchanged
in the gastrointestinal tract (Gugler, Leschik et al. 1975). This is not surprising
given that QUE has extremely low water solubility, a major factor in drug
absorption.

Not only is QUE absorbed poorly, but also it is conjugated

extensively in the liver following oral administration (Reinboth, Wolffram et al. ;
Manach, Morand et al. 1997; Ader, Wessmann et al. 2000). In dogs, more than
80% of the circulating flavonols existed as conjugated metabolites (Reinboth,
Wolffram et al.).

Since many of the proposed health effects of QUE were

observed in vitro with the unconjugated aglycone, it is questionable whether the
QUE metabolites will remain bioactive.
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Few investigators have studied the

	
  

bioactivity of QUE metabolites and those that do typically only look at one
potential clinical indication for QUE. Spencer et al studied the bioactivity of in
vivo QUE metabolites. They found that 3′-O-methyl quercetin and 4′-O-methyl
quercetin had a reduced capacity to protect fibroblasts from peroxide-induced
cell damage, whereas quercetin 7-O-β-D-glucuronide was completely inactive
(Spencer, Kuhnle et al. 2003). Even though this study only investigated one
activity of QUE, it is probable that the in vivo effectiveness of QUE will be limited
by its absorption and metabolism.
Thus, novel strategies that can increase the absorption of QUE or affect
its metabolism are desirable.
several

methods

for

The pharmaceutical industry typically employs

correcting

compounds

that

exhibit

undesirable

physicochemical characteristics including screening for salts, polymorphs, and
hydrates/solvates of the active pharmaceutical ingredient (API) (Shan and
Zaworotko 2008).

However, one long known methodology has remained

relatively unexplored by many.

Cocrystallization is beginning to attract the

attention of the pharmaceutical industry because it can be used to both modify
the physicochemical properties of a compound without affecting the intrinsic
bioactivity and extend the product life of the API (Sarma, Chen et al. 2011).
Cocrystals have been defined as “a multiple component crystal in which all
components are solid under ambient conditions when in their pure form” (Shan
and Zaworotko 2008). The API and cocrystal former(s) exist at a stoichiometric
ratio and form complexes that are generally stabilized by hydrogen bonds. This
technique has been used to improve the physicochemical properties of numerous
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different APIs (Cheney, Weyna et al. ; Yadav, Dabke et al. ; Brader, Sukumar et
al. 2002; Remenar, Morissette et al. 2003; Childs, Chyall et al. 2004; McNamara,
Childs et al. 2006; Hickey, Peterson et al. 2007; Bak, Gore et al. 2008; Basavoju,
Bostrom et al. 2008). Most notably, cocrystallization is often used to modulate
the solubility of an API.

Whenever solubility is a limiting factor in the

bioavailability of a compound (like with QUE), modulation of solubility can
produce drastic effects.

Thus, we determined that QUE would be a good

candidate for cocrystallization.
In this report, we evaluate the solubility and pharmacokinetic profile of four
novel QUE cocrystals. Each of the cocrystals described were selected due to
improved physicochemical properties that we hypothesized would lead to
improved bioavailability.
4.2 Materials and Methods
4.2.1 Reagents
Quercetin dihydrate (98% purity), Isonicotinamide (INM) (99% purity), Caffeine
(CAF), and Theobromine (TBR) (98% purity) were purchased from Sigma-Aldrich
Corporation (St. Louis, MO, USA).
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4.2.2 Synthesis of the cocrystals

Figure 4.1
QUE cocrystal reaction sheme.
QUECAF•MeOH: QUE dihydrate (34.0 mg, 0.101 mmol) and CAF (19.0 mg,
0.100 mmol) were dissolved in 6 mL of methanol by heating.

The resulting

solution was placed in a refrigerator overnight. Golden yellow crystals of the
cocrystal were harvested (melting point = 246oC).
QUECAF: The cocrystal was prepared by desolvating QUECAF•·MeOH. It was
prepared by overnight slurrying of QUE dihydrate (101.46 mg, 0.300 mmol) and
caffeine (58.23 mg, 0.300 mmol) in 2 mL of methanol. The solid was filtered and
dried in the vacuum oven for 3 hours at 150 oC, thereby affording QUECAF.
(melting point of dried solid = 245.95oC).

	
  

36	
  

	
  

QUEINM: QUE dihydrate (34.0 mg, 0.101 mmol) and INM (12.3 mg, 0.100 mmol)
were dissolved in 6 mL of methanol by heating on a hotplate. The resulting
solution was placed in a refrigerator.

After 2 days, yellow plate crystals of

QUEINM were obtained (melting point = 262oC).
QUETBR•2H2O: QUE dihydrate (33.8 mg, 0.099 mmol) and TBR (18.0 mg, 0.
099mmol) were dissolved in 5 mL of ethanol and 10 mL of 1:1 mixture of water
and ethanol respectively by heating. Resulting solutions were filtered together
and placed in the refrigerator for slow evaporation. The crystals were harvested
after 4 days (melting point = 293.8oC).
Synthesis of cocrystals in bulk for dissolution:
The cocrystals were made in bulk for dissolution study by slurry method. For
each cocrystal stoichiometric amounts of the starting materials in 5-6 mL of
methanol and stirred overnight with the help of a magnetic stir bar on a stir plate,
which produces the cocrystals with 100% yield. The purity of the bulk material is
tested by powder X-ray diffraction (PXRD) and differential scanning calorimetry
(DSC). For PXRD pattern of the bulk material is compared to the PXRD obtained
from the single crystal X-ray diffraction and presence of any additional peaks
other than the peaks in the calculated pattern indicates starting materials or
impurities. Likewise, the DSC of the bulk cocrystal exhibit endotherm for the
melting point of the cocrystals and the desolvation/dehydration.
4.2.3 Characeterization of Cocrystals
Differential scanning calorimetry (DSC): Thermal analysis was performed on a
TA Instruments DSC 2920 Differential Scanning Calorimeter. Aluminum pans
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were used for all samples and the instrument was calibrated using an indium
standard. For reference, an empty pan sealed in the same way as the sample
was used. Using inert nitrogen conditions, the samples were heated in the DSC
cell from 30 °C to the required temperature (melting point of the cocrystal) at a
rate of 10°C/min.
Infrared spectroscopy (FT-IR): To characterize the cocrystals by infrared
spectroscopy a Nicolet Avatar 320 FT-IR instrument was used. Sample amounts
of 1-2 mg were used and spectra were measured over the range of 4000–400cm1

and analyzed using EZ Omnic software.

Ultraviolet/Visible Spectroscopy (UV/vis): UV/vis analysis was performed on a
Perkin-Elmer Lambda 900 UV/VIS/NIR spectrometer.
Powder X-ray diffraction (PXRD): A Bruker AXS D8 powder diffractometer was
used for all PXRD measurements with experimental parameters as follows: Cu
Kα radiation (λ = 1.54056 Ǻ); 40 kV and 30 mA. Scanning interval: 3–40° 2θ; time
per step: 0.5 sec.

The experimental PXRD patterns and calculated PXRD

patterns from single crystal structures were compared to confirm the composition
of bulk materials.
Single-Crystal X-ray Data Collection and Structure Determinations: Suitable
crystals for X-ray crystallography were selected using an optical microscope.
The X-ray diffraction data were collected on Bruker-AXS SMART-APEXII CCD
diffractometer using Cu Kα (λ = 1.54178 Å) for QUECAF•MeOH and Mo Kα
radiation (λ = 0.71073 Å) for QUEINM. Indexing was performed using APEX2
(2010) (Difference Vectors method). Data integration and reduction were
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performed using SaintPlus 6.01 (2009). Absorption correction was performed by
multi-scan method implemented in SADABS (Sheldrick 2008). Space groups
were determined using XPREP implemented in APEX2 (2010). The structure
was solved using SHELXS-97 (direct methods) and refined using SHELXL-97
(full-matrix least-squares on F2) contained in APEX2 (2010) and WinGX v1.70.01
(Sheldrick 1990; Sheldrick 1997; Farrugia 1999) program packages. All nonhydrogen atoms were refined anisotropically. Hydrogen atoms were placed in
geometrically calculated positions and included in the refinement process using
riding model with isotropic thermal parameters: Uiso(H) = 1.5Ueq(-CH3,-OH),
Uiso(H) = 1.2Ueq(-CH). Hydrogen atoms of the NH2 group were found on a
difference Fourier map and were freely refined.
4.2.4 Solubility evaluation
Solubility studies were performed on QUECAF•MeOH, QUECAF, QUEINM, and
QUETBR•2H2O using 1:1 mixture of water and ethanol as QUE could not be
quantified by using UV/VIS/NIR spectrophotometry in water alone. However the
solubility of QUE and its dihydrate in water has been reported by Srinivas et al as
0.00215 mg/mL and 0.00263 mg/mL respectively (Srinivas, King et al. 2010).
Each of the cocrystal was synthesized in bulk by taking stoichiometric ratios of
the starting materials in methanol and slurrying them for 24 hours, which
produced the cocrystals in 100% yield.

The slurries were dried at room

temperature and were sieved to attain a particle size between 53 and 75 µm.
The solubility study was done by taking approximately 4 grams of the cocrystal in
30 mL of water and was stirred with magnetic stir bar at ca. 125 rmp for 24 hours.
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The solubility studies were conducted by taking approximately 4 grams of the
cocrystal in 70 mL of 50% ethanol and were stirred with magnetic stir bar at ca.
125 rmp for 24 hours at room temperature. Aliquots were drawn from the slurry at
regular time intervals (5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 75, 90, 105,
120, 150, 180, 240 and 1440 minutes) and filtered using a 0.45 µm nylon filters.
The filtrates were immediately diluted appropriately and were analyzed to
measure the concentration of QUE by using UV/VIS/NIR spectrometer at 360 nm
where the interference of the cocrystals formers was not observed.

The

remaining solids were analyzed by PXRD and DSC. The solubility measurements
were done in replicates of three.
4.2.5 Pharmacokinetic screening of quercetin formulations in rats
Male Sprague Dawley rats (n=3 per group) weighing 200-250 g were purchased
from Harlan Laboratories (Indianapolis, IN).

The rats were purchased pre-

cannulated by Harlan. The rounded tip catheters were surgically implanted into
the jugular vein of the rats making multiple, precise blood draws painless to the
animal. The rats were food (not water) deprived for 18 hours prior to the start of
the experiment. Vegetable oil was selected as the gavage vehicle because all
crystal forms were observed to be insoluble in it. The QUE formulations were
delivered via oral gavage at a dosage of 100 mg quercetin/kg body weight.
Blood was collected at the following time points: 0, 5, 10, 30, 60, 120, 240, and
480 minutes. Because heparin was kept in the catheter lines to prevent clotting,
a small amount of blood was drawn and discarded before collecting each
sample. Approximately 300 µL of blood was collected in EDTA tubes for each
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time point.

The samples were kept on ice to preserve their integrity, then

centrifuged at 4000 rpm for 10 minutes, after which the plasma was transferred
to sterile centrifuge tubes. A preservative solution was added to each plasma
sample at 10% (v/v) concentration to ensure the integrity of the QUE during
storage (Lambert, Lee et al. 2006). This preservative was comprised of 20%
ascorbic acid (to prevent oxidation) and 0.1% EDTA (to scavenge any metal
contaminants). The samples were stored at -80°C until they were analyzed for
QUE content.
4.2.6 Quantification of QUE in Rat Plasma
The plasma samples were analyzed for QUE content by the Burnham Institute for
Medical Research Pharmacology Core (Orlando, FL). To accurately quantify the
concentration of QUE in the plasma, a previously described method was
employed using liquid chromatography with tandem mass spectrometry (Wang
and Morris 2005). The standards were prepared as follows. A 2.00 mg/mL stock
solution of QUE was accurately prepared in DMSO. The stock solution was
protected from light using amber vials and stored at -20°C. Standards were
prepared using the appropriate blank rat plasma with the ascorbic acid and
EDTA preservative.

The samples were aliquotted into pre-labeled 1.7 mL

microcentrifuge tubes. 100 µL was used as the aliquot volume for all samples.
Except for the double blanks, 400 µL of the internal standard spiking solution
(Naproxen, 2.00 µg/mL in ACN) was added to all samples. Tubes were then
capped, vortexed for 3 minutes and centrifuged for 10 minutes at 14,000 rpm.
Approximately 300 µL was then transferred from each tube into a 96-well plate
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for analysis by LCMSMS. The concentration range of the standard curve was 10
µg/mL to 0.100 µg/mL of QUE. The results indicated that the standard curve
performance was within acceptable range for bioanalytical method acceptance
(R2> 0.99) (Wang, Hop et al. 2000; Sparidans, Lagas et al. 2007; Wang and
Miksa 2007).
4.2.7 Pharmacokinetic Calculations
Mean plasma QUE concentrations and the standard error in the mean (SEM)
were graphed using GraphPad PRISM software (GraphPad Software, Inc.).
Pharmacokinetic parameters were determined using a commercially available
computer modeling program, PK Solutions v2.0.7 (Summit Research Services,
Ashland, OH). The reported pharmacokinetic parameters included CMAX, TMAX,
area under curve (AUC), relative bioavailability (FREL), absorption half life (A T1/2),
distribution half life (D T1/2), and elimination half life (E T1/2).

Relative

bioavailability was determined by dividing the AUC of each QUE formulation by
the control.
Statistical Analysis
A post hoc t-test with Bonferroni correction was used to assess the statistical
significance at each time point for the pharmacokinetic study.

Each QUE

cocrystal was compared to the QUE dihydrate control. The criterion for rejection
of the null hypothesis was P<0.05.
4.3 Results
4.3.1 Dissolution study of the QUE cocrystals
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QUE has very poor water solubility. In fact, when we tried to determine the water
solubility of QUE dihydrate it was below our lower limit of detection. Therefore,
1:1 ethanol/water solvent mixture was used for the dissolution studies. The
solubility of QUE dihydrate in 1:1 ethanol/water solvent mixture is found to be
0.267 mg/mL.

We found that the QUECAF and QUECAF•MeOH cocrystals

exhibit the highest solubilities. The maximum solubilities exhibited by QUECAF,
QUECAF•MeOH, QUEINM, QUETBR•2H2O cocrystals were 3.627, 2.018, 1.22
and 0.326 mg/mL respectively. From the dissolution profiles it is evident that
QUECAF

(desolvated

form

of

QUECAF•MeOH)

displayed

the

highest

concentration of QUE. This cocrystal increased the solubility of QUE by 14 fold,
and the lowest was by QUETBR•2H2O, which was only slightly improved over
QUE alone. Figure 4.2 represents the dissolution profiles of QUE dihydrate and
its cocrystals in the first 4 hours and Figure 4.3 in 24 hours. From the DSC and
PXRD obtained from the leftover powders after 24-hour dissolution reveal that
QUECAF, QUECAF•MeOH, QUETBR•2H2O and QUEINM convert back to QUE
dihydrate.
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Figure 4.2
Dissolution profiles of QUE dihydrate and its cocrystals in 1:1 ethanol/water mixture (a)
first 4 hours.

Figure 4.3
Dissolution profiles of QUE dihydrate and its cocrystals in 1:1 ethanol/water mixture (a)
first 4 hours.
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4.3.2 Pharmacokinetics of the QUE cocrystals
We hypothesized that the improvements in solubility would lead to improved
bioavailability for the QUE cocrystals. This hypothesis was supported in our
preliminary pharmacokinetic evaluation. The pharmacokinetic curves are shown
in Figure 4.4.

Figure 4.4
Pharmacokinetic profiles (mean plasma concentration + SEM versus time).
There were n=3 rats per group. Statistical significance was achieved for
QUEINM at t=10 (p<0.01) and for QUECAF•MeOH at t=5 (p<0.001).
As expected, the QUE dihydrate was absorbed very poorly. In fact, only one of
the three rats exhibited levels of QUE that were above our lower limit of
quantification (0.100 µg/mL) and only at one time point, the TMAX, t=30 minutes.
This is easily explained by the extremely poor solubility of QUE dihydrate.
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Because the QUE dihydrate was so poorly absorbed, we were unable to
calculate half-life values for the three pharmacokinetic phases (absorption,
distribution, and elimination).

All four of the cocrystals exhibited favorable

solubility and improved pharmacokinetic parameters.

These pharmacokinetic

parameters including the TMAX, CMAX, AUC, FREL, A T1/2, D T1/2, and E T1/2 can be
found in Table 4.1. Interestingly, the QUETBR•2H2O cocrystal was only slightly
more soluble than QUE dihydrate but exhibited vastly superior pharmacokinetic
properties. The QUETBR•2H2O cocrystal had the highest FREL at 9.93. This
means that the AUC was nearly 10-fold higher than with QUE dihydrate.
Additionally, the elimination of QUETBR•2H2O appears to be slowed. The E

T1/2

was the highest for this cocrystal at 145 minutes (Table 4.1). All of the cocrystals
reached systemic circulation more quickly than the QUE control, which is
consistent with the improved solubility. Perhaps most importantly, the relative
bioavailability (FREL) was much higher with the cocrystals. QUEINM had the
second greatest FREL at 5.46, followed by the QUECAF•MeOH and QUECAF at
4.01 and 2.57, respectively. The E T1/2 followed the same trend as the FREL. The
QUEINM exhibited an E T1/2 of 77 minutes and the QUECAF•MeOH and
QUECAF cocrystals were 52 and 26 minutes, respectively.
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Table 4.1. Pharmacokinetic Parameters
QUE

QUEINM

QUECAF•MeOH

QUECAF

QUETBR•2H2O

TMAX(min)

30

10

5

10

5

CMAX(ng/mL)

285

1401

2612

656

840

AUC (ng•min/mL)

7493

40921

30084

19232

74430

FREL

1

5.46

4.01

2.57

9.93

A T1/2 (min)

N/A

3.260

2.378

2.682

1.656

D T1/2 (min)

N/A

5.291

5.091

3.568

8.610

E T1/2 (min)

N/A

76.934

52.447

26.381

145.309

4.3.3 Crystal structures of the QUE cocrystals
Table 4.2. Crystallographic data and structure refinement parameters for the
cocrystals reported herein.
Formula
MW
Crystal system
Space group
a (Å)
b (Å)
c (Å)
α (deg)
β (deg)
γ (deg)
V /Å3
Dc/mg m-3
Z
2θ range
Nref./Npara.
T /K
R1 [I>2sigma(I)]
wR2
GOF
Abs coef.

QUEINM
C21H16N2O8
424.36
Triclinic
P-1
4.978 (1)
12.636 (3)
15.571 (3)
110.53 (3)
97.63 (3)
99.39 (3)
885.7 (3)
1.5913
2
2.66 to 24.93
2999/292
100 (2)
0.0592
0.1267
1.091
0.124

QUECAF•MeOH
C24H24N4O10
528.47
Monoclinic
P2(1)/c
10.309 (3)
14.853(4)
15.199 (5)
90
100.612 (2)
90
2287.51 (12)
1.535
4
4.20 to 67.88
4031/353
100 (2)
0.0434
0.1090
1.035
0.1033

QUEINM: The 1:1 cocrystal of QUEINM contains two molecules of QUE and
INM in the unit cell and crystallizes in P-1 space group. The catechol moiety of
QUE molecules form the O···O-H supramolecular homosynthon with hydrogen
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bond distance of 2.765 (3) Å. The carbonyl and the syn-hydrogens of the amide
functionality of INM molecules hydrogen bond to the catechol dimer on either
side and results in the formation of a ring described by 𝐑𝟐𝟐   (8) graph set(Etter,
MacDonald et al. 1990) (N-H···O: 2.610 (3) Å and O···O-H: 3.028 (4) Å). Thus, a
four-component assembly is generated by two molecules of INM and QUE
molecules which can be described by 𝐑𝟒𝟒 (18) graph set. The Narom and the antihydrogen of the amide moiety of INM molecules interacts with one of the O-H
moieties (O-H···Narom: 2.688 (3) Å· and the carbonyl moieties (O···N-H: 3.019 (3)
Å of QUE molecule respectively. The supramolecular interactions between QUE
and INM molecules in QUEINM cocrystal overall lead to the generation of a 2-D
sheet as shown in Figure 4.5.
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Figure 4.5
Representation of supramolecular sheet in QUEINM. In the the cocrystal the
QUE and INM molecules interact via O-H···Narom supramolecular H-bonds. Two
QUE molecules form the catechol dimer through O-H···O H-bonds and the amide
functionalities of the INM molecules H-bond on either side of the catechol dimer.
Overall H-bonding results in the generation of supramolecular sheet.
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Table 4.2. Crystallographic data and structure refinement parameters for the cocrystals
reported herein.
Formula
MW
Crystal system
Space group
a (Å)
b (Å)
c (Å)
α (deg)
β (deg)
γ (deg)
V /Å3
Dc/mg m-3
Z
2θ range
Nref./Npara.
T /K
R1 [I>2sigma(I)]
wR2
GOF
Abs coef.

QUEINM
C21H16N2O8
424.36
Triclinic
P-1
4.978 (1)
12.636 (3)
15.571 (3)
110.53 (3)
97.63 (3)
99.39 (3)
885.7 (3)
1.5913
2
2.66 to 24.93
2999/292
100 (2)
0.0592
0.1267
1.091
0.124

QUECAF•MeOH
C24H24N4O10
528.47
Monoclinic
P2(1)/c
10.309 (3)
14.853(4)
15.199 (5)
90
100.612 (2)
90
2287.51 (12)
1.535
4
4.20 to 67.88
4031/353
100 (2)
0.0434
0.1090
1.035
0.1033

QUECAF•MeOH: This cocrystal crystallizes in a P21/c space group. The Narom of
the imidazole ring and the CO of the imide ring of CAF interacts with O-H
moieties of QUE through O-H···Narom (2.821 (3) Å) and CO···O-H (2.716 (3) Å)
hydrogen bonds.

Both the O-H in the catechol moiety of QUE molecule

hydrogen bond to the O-H of neighboring QUE molecule through O-H···O and
O···O-H ((2.774 (3) Å and 2.847 (3) Å respectively).

Supramolecular

heterosynthons: One of the O-H adjacent to the CO functionality engages in a
strong intramolecular H-bonding (2.602 (3) Å). The methanol molecule interacts
with the remaining CO group on the imide ring of CAF molecule with a hydrogen
bond distance of 2.712 (3) Å. The overall interaction between QUE, CAF and
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MeOH results in the formation of a supramolecular sheet as shown in Figure 4.6.

	
  

Figure 4.6
Intermolecular hydrogen bonding in QUECAF•MeOH. QUE molecules interact
with CAF molecules through O-H···Narom and O-H···C=O supramolecular H-bonds
and the MeOH molecules just interact with the CAF molecules. A supramolecular
sheet is produced by hydrogen bonding between QUE, CAF and MeOH
molecules.
The MeOH molecules in one layer interact with one of the O-H of the catechol
moieties of QUE in another supramolecular sheet through O···O-H hydrogen
bonds. This results in the formation of bilayers as shown in Figure 4.7.

Figure 4.7
Illustration of bilayers in QUECAF•MeOH. Each supramolecular sheet in
QUECAF•MeOH interats with the other other sheets through MeOH molecules
and results in the formation of bilayers which can be described as ABAB and so
on.
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The crystal structure of QUETBR•2H2O has been published elsewhere (Clarke,
Arora et al. 2010). The crystal structure of QUECAF has not been determined
yet but the chemical identity of the cocrystal is confirmed from the PXRD, IR,
DSC and TGA.

The PXRD reveals that QUECAF is isostructural to

QUECAF•MeOH (Figure 4.8a) and the DSC confirms that after the loss of MeOH
molecule from QUECAF•MeOH the cocrystal is still stable and has the same
melting point as that of the solvated one (Figure 4.8b).

	
  
Figure 4.8a
Comparison PXRDs of QUECAF•MeOH and QUECAF; (b) Comparison of DSCs
of QUECAF•MeOH and QUECAF. The PXRD patterns of QUECAF•MeOH
calculated and experimental (bulk powder) matches exactly indicating the total
conversion of the starting materials into cocrystal and no presence of starting
materials. The similarity in the PXRD patterns of QUECAF•MeOH and QUECAF
indicates isostructural nature of both cocrystals.
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Figure 4.8b
Comparison of DSCs of QUECAF•MeOH and QUECAF. The DSC of QUECAF
reveals that the crystal packing is intact even after the removal of MeOH
molecule as its melting point matches with that of QUECAF•MeOH.
4.4 Discussion and Conclusion
Given that QUE exhibits numerous useful bioactivities it is not surprising
that it remains to be studied even after the discovery of its poor bioavailability in
1975 (Gugler, Leschik et al. 1975). Since then, there have been several followup reports of QUE deposition and bioavailability in various animal models
(Manach, Morand et al. 1997; Manach, Texier et al. 1999; Ader, Wessmann et al.
2000; Morand, Manach et al. 2000; Cermak, Landgraf et al. 2003; Khaled, ElSayed et al. 2003; Lesser, Cermak et al. 2004; Mullen, Rouanet et al. 2008).
The reoccurring theme in the existing literature is that QUE is present in systemic
circulation mainly as conjugated metabolites. Piskula et al (1998) studied the
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bioavailability of QUE in various vehicles in a rat model and reported circulating
levels of QUE and its metabolites (Piskula and Terao 1998). Not surprisingly, the
free, unconjugated QUE was detected only when QUE was administered in a
propylene glycol vehicle, in which it was most soluble compared to the other
vehicles.

They later hypothesized that this phenomenon was likely due to

animals’ overdosing.

It is not clear whether they meant experimental error

(animals given more than 50 mg/kg) or a saturation of liver first pass enzymes
due to more rapid absorption in the vehicle that exhibited the highest solubility.
Either of these are feasible explanations. Nonetheless, it was clear that QUE
was present in vivo mainly as a conjugated metabolite and that its solubility was
an important factor in overall absorption.

The premise that modulating the

solubility of QUE could affect its absorption is what fueled our study and others
before it. Kim et al (2009) reported several new quercetin-amino acid conjugates
that exhibited improved water solubility and in vitro stability and permeability
(Kim, Park et al. 2009).

Even though this will presumably lead to improved

bioavailability, this remains to be seen due to the lack of an in vivo evaluation.
In this study, we evaluated the bioavailability of four cocrystals of QUE
with varying degrees of improved water solubility in comparison to QUE alone.
Our in vivo pharmacokinetic evaluation is in agreement with existing literature in
that modulating solubility did impact absorption patterns of the QUE cocrystals.
Since solubility often limits the rate of absorption of a compound, one would
expect that improving the solubility of a poorly soluble compound would shift to
the left the time at which maximal plasma levels were achieved. This was the
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case for all of the cocrystals presented in this study. In table 4.1, the QUE
dihydrate control had a TMAX of 30 minutes, whereas the cocrystals peaked at 5
and 10 minutes. Not only did the QUE cocrystals reach systemic circulation
more quickly than QUE dihydrate but they also reached significantly higher
concentrations. The QUECAF•MeOH cocrystal peaked rapidly at 5 minutes with
7.7 µM free QUE. For comparison, the QUE dihydrate control peaked at 30
minutes with 0.84 µM QUE aglycone.
Even though solubility is a limiting factor of the oral bioavailability of QUE,
it is apparent that it is not the only factor. Modulation of metabolism can also
have drastic effects on oral bioavailability. Recently, one study reported that
several ester-based precursors to QUE might be useful for increasing systemic
aglycone concentrations (Biasutto, Marotta et al. 2007).

The investigators

demonstrated that some ester precursors were resistant to phase II conjugation
by tight monolayers of MDCK-1, MDCK-2, and Caco-2 cells. They hypothesize
that in vivo the residual acyl groups will be eliminated leaving the QUE aglycone
that is known to be bioactive. Although this data is promising, the study is limited
due to the lack of in vivo evaluation. Additionally, one of the major limitations to
QUE is its very low water solubility. Each of these precursors was reported to
exhibit solubility similar to QUE. This might pose a formulation dilemma due to
insolubility and poor dissolution at physiologically relevant doses in vivo.
Interestingly, post-hoc analysis of the pharmacokinetic curve (Fig 4.4)
revealed that modulation of solubility is probably not the only contributing factor
to the improved bioavailability of some of the QUE cocrystals. This is evident
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when the relative solubilities of each cocrystal (Fig 4.3) are compared to the
pharmacokinetic profile (Fig 4.4).

Based on solubility differences alone, the

QUECAF cocrystal would be expected to have the highest CMAX since it would be
solubilized, and thus absorbed, more completely than the others. However, the
QUECAF cocrystal had the lowest CMAX of all of the cocrystals, peaking at just
656 ng/mL at 10 minutes. Furthermore, the QUEINM cocrystal had the second
lowest solubility and caused systemic QUE aglycone levels to reach 1401 ng/mL,
second only to the QUECAF•MeOH cocrystal. Therefore, there must be factors
other than solubility at play. It is possible that the INM might reduce the first pass
effect of the liver enzymes on QUE.

Perhaps most interesting is the

pharmacokinetic profile of the QUETBR•2H2O cocrystal (Fig 4.4). Despite having
a solubility that is only slightly higher than QUE dihydrate, this cocrystal achieved
sustained levels of quercetin aglycone, indicative of modulated elimination. The
resultant FREL of the QUETBR•2H2O cocrystal was 9.93, the largest increase
observed in this study (Table 4.1). This cocrystal also exhibited the longest E
T1/2, 145 minutes (Table 4.1). Still, we cannot reach any definitive conclusion
about the metabolism of the cocrystals since we did not measure circulating QUE
metabolites.
These results add to existing evidence that cocrystallization is a useful
methodology for improving the physicochemical properties of a compound and
that these improvements can lead to drastically enhanced bioavailability when
applied to compounds that are limited by their solubility. This same ideology was
previously shown to be successful in several preclinical studies. Carbamazepine
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(CBZ) is used for the treatment of epilepsy and bipolar disorder but also suffers
from low solubility and oral bioavailability. Cocrystals of CBZ and saccharin were
administered orally to dogs and were found to achieve greater plasma
concentrations than the API alone (Hickey, Peterson et al. 2007).

This

improvement in bioavailability was attributed to the improved solubility of the
cocrystal.

AMG 517, VR1 (vanilloid receptor 1) antagonist is a practically

insoluble drug, which limits its bioavailability.

Bak et al reported that the

cocrystallization of AMG 517 with sorbic acid dramatically increases its
bioavailability in rats (Bak, Gore et al. 2008).

Similarly, Jung et al used

cocrystallization to improve the solubility, and consequent bioavailability of
indomethacin (Jung, Kim et al. 2010). Thus, modulating the solubility of a poorly
soluble API using cocrystallization appears to be a proven, highly effective, and
broadly applicable method for improving oral bioavailability.
Taken with the existing evidence from the literature, the results of this
study further implicate the potential for cocrystallization in drug development.
One limitation is that the plasma samples were analyzed for free, unconjugated
QUE content alone.

This is because modulated metabolism was not an

expected outcome of cocrystallization. However, given the unexpected
discrepancies between the solubility and pharmacokinetic profiles of the
cocrystals, modulated metabolism is probable. Future studies should investigate
whether cocrystallization with certain cocrystal formers can be used to modulate
the metabolism of the API. Nevertheless, this study implicates cocrystallization
as a potential solution to the solubility and bioavailability problems that thwart the
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success of QUE as an effective treatment option for its numerous clinical
indications.
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CHAPTER 5
MODULATING THE SOLUBILITY OF EGCg USING COCRYSTALLIZATION
AND ITS EFFECTS ON PHARMACOKINETICS

5.1 Introduction
EGCg and it’s therapeutic uses, metabolism, and problematic clinical
translation are discussed in detail in Chapter 1.

Due to extremely poor

bioavailability, novel methods for improving its absorption and/or therapeutic
efficacy are desirable. Nanolipidic particles were used to improve the absorption
of EGCg in Chapter 3.

This chapter aims to modulate the dissolution, and

consequent pharmacokinetics of EGCg using cocrystallization.
In the previous chapter, modulating the solubility of quercetin using
cocrystallization drastically improved its bioavailability.
quercetin, EGCg is highly soluble in water.

However, unlike

Therefore, it was selected to

determine the effects that reducing the solubility through cocrystallization might
have on the pharmacokinetic profile. Compounds that are highly water-soluble
are typically absorbed well in the gastrointestinal tract but are consequently
easily excreted and, thus, exhibit low half lives (T1/2). We hypothesized that we
could improve the circulation time of EGCg by reducing its water solubility
through cocrystallization. This chapter will describe the synthesis, solubility, and
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bioavailability of four new EGCg cocrystals: EGCg/Nicotinamide hydrate
(EGCgNIC•9H2O),
EGCg/Isonicotinic

EGCg/Isonicotinamide
Acid

(EGCgINA),

hydrate

(EGCgINM•5H2O),

EGCg/Isonicotinic

Acid

hydrate

(EGCgINA•3H2O).
5.2 Materials and Methods
5.2.1 Reagents
EGCg (>95% purity by HPLC) was purchased from www.herbs-tech.com.
Isonicotinamide (INM) (99% purity), Nicotinamide (99% purity), and Isonicotinic
Acid (99% Purity) were purchased from Sigma-Aldrich Corporation (St. Louis,
MO, USA).
5.2.2 Synthesis of the cocrystals

EGCgINM•5H2O,
,

EGCgNIC•9H2O,
,

EGCg,
Isonico'namide,

Nico'namide,

H2O,

H2O,

Isonico'nic,Acid,
H2O,

85oC,,

EGCgINA•3H2O,

EGCgINA,

Figure 5.1
EGCg cocrystal reaction scheme.
	
  

60	
  

	
  

EGCgNIC•9H2O: EGCg (90% pure, 45.83 mg, 0.1000 mmol) and nicotinamide
(99% pure,12.21 mg, 0.1000 mmol) were dissolved in 2 mL of water. Colorless
crystals were harvested after 3 days. The cocrystal can also be obtained by
solvent drop grinding and slurrying with water. (melting point = 90.0 oC).
EGCgINM•5H2O: EGCg (90% pure, 45.83 mg, 0.1000 mmol) and isonicotinamide (99% pure, 12.21 mg, 0.1000 mmol) were dissolved in 6 mL of
water. Colorless crystals were harvested after ca. 5 minutes. (melting point =
155.0 oC).
EGCgINA•3H2O: EGCg (90% pure, 45.83 mg, 0.1000 mmol) and isonicotinic acid
(99% pure, 12.31 mg, 0.1000 mmol) were dissolved in 10 mL of water. Colorless
crystals were harvested after 1 day. The cocrystal can also be obtained by
solvent drop grinding and slurrying with water. (melting point = 190 oC).
EGCgINA: EGCg (90% pure, 45.83 mg, 0.1000 mmol) and isonicotinic acid (99%
pure, 12.31 mg, 0.1000 mmol) were dissolved in 10 mL of water. Colorless
crystals were harvested after 1 day. The cocrystal can also be obtained by
solvent drop grinding and slurrying with water. The cocrystal loses water after
heating, converting to an anhydrous cocrystal. (melting point = 190 oC).
5.2.3 Solubility evaluation
Solubility studies were performed on EGCgNIC•9H2O, EGCgINM•5H2O,
EGCgINA•3H2O, and EGCgINA. Each of the cocrystals was synthesized in bulk
by taking stoichiometric ratios of the starting materials in methanol and slurrying
them for 24 hours, which produced the cocrystals in 100% yield. The slurries
were dried at room temperature and were sieved to attain a particle size between
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53 and 75 µm. The solubility study was done by taking approximately 4 grams of
the cocrystal in 30 mL of water and was stirred with magnetic stir bar at ca. 125
rmp for 24 hours. Aliquots were drawn from the slurry and filtered using a 0.45
µm nylon filters. The remaining solid was analyzed by PXRD and DSC. For
every cocrystal, 1mL of the filtered solution from the slurry was transferred into a
pre-weighed (w1) vial by using an analytical balance and was put on a hot plate
(maintained at 50 oC) to evaporate the water. The vial was weighed again (w2)
and the difference in the weights (w2-w1) gave the weight of the cocrystal in 1ml
of water from which the weight of EGCg was calculated. The solubility studies
and the gravimetric methods were done in replicates of three.
5.2.4 Pharmacokinetic screening of EGCg formulations in rats
Male Sprague Dawley rats (n=3 per group) weighing 200-250 g were purchased
from Harlan Laboratories (Indianapolis, IN).

The rats were purchased pre-

cannulated by Harlan. The rounded tip catheters were surgically implanted into
the jugular vein of the rats making multiple, precise blood draws painless to the
animal. The rats were food (not water) deprived for 18 hours prior to the start of
the experiment. Vegetable oil was selected as the gavage vehicle because all
crystal forms were observed to be insoluble in it. Crystallographic data was used
to calculate the equivalent weight of each multiple component cocrystal to
provide a 100 mg/kg dose of EGCg (Mukherjee, Clarke et al. 2011). The EGCg
formulations were delivered via oral gavage at a dosage of 100 mg EGCg/kg
body weight. Blood was collected at the following time points: 0, 5, 10, 30, 60,
120, 240, and 480 minutes. Because heparin was kept in the catheter lines to
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prevent clotting, a small amount of blood was drawn and discarded before
collecting each sample. Approximately 300 µL of blood was collected in EDTA
tubes for each time point.

The samples were kept on ice to preserve their

integrity, then centrifuged at 4000 rpm for 10 minutes, after which the plasma
was transferred to sterile centrifuge tubes. A preservative solution was added to
each plasma sample at 10% (v/v) concentration to ensure the integrity of the
EGCg during storage (Lambert, Lee et al. 2006).

This preservative was

comprised of 20% ascorbic acid (to prevent oxidation) and 0.1% EDTA (to
scavenge any metal contaminants). The samples were stored at -80°C until they
were analyzed for EGCg content.
5.2.5 Quantification of EGCg in rat plasma
Refer to 2.7.1.
5.2.6 Statistical analysis
A post hoc t-test with Bonferroni correction was used to assess the statistical
significance at each time point for the pharmacokinetic study.

Each EGCg

cocrystal was compared to the EGCg control. The criterion for rejection of the
null hypothesis was P<0.05.
5.3 Results
5.3.1 Crystallography
EGCgNIC•9H2O:

The single crystal x-ray diffraction data revealed that

EGCgNIC•9H2O is a 2:2 cocrystal of EGCg and nicotinamide with 9 water
molecules. The intermolecular hydrogen bonding of the cocrystal is shown in
Figure 5.2.
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Figure 5.2
EGCgNIC•9H2O intermolecular hydrogen bonds. The intermolecular hydrogen
bonds are indicated by blue dotted lines on the left. As a hydrate, water
molecules exist in the crystal structure and are indicated by red balls on the right.
EGCgINM•5H2O:

The single crystal x-ray structure analysis revealed that

EGCgINM•5H2O is a hydrated, 1:1 cocrystal of EGCg and isonicotinamide.
EGCg molecules and isonicotinamide molecules interact through single-point
hydrogen bonds (O-H···N, O···N: 2.756Å) between the hydroxyl group of EGCg
molecule and the aromatic nitrogen of isonicotinamide molecules. These dimeric
units are connected further by O-H···O (O···O: 2.662Å) hydrogen bonds formed
between the hydroxyl moieties of EGCg and carbonyl moieties of isonicotinamide
molecules. This results in the zig-zag chain formation shown in Figure 5.3.

	
  
Figure 5.3
EGCgINM•5H2O intermolecular hydrogen bonds. The intermolecular hydrogen
bonds are indicated by blue dotted lines.
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EGCgINA•3H2O:

The single crystal x-ray structure analysis revealed that

EGCgINA•3H2O is a trihydrate co-crystal of EGCG and nicotinamide at a 1:1
ratio. The intermolecular hydrogen bonds are illustrated in Figure 5.4.

Figure 5.4
EGCgINA•3H2O intermolecular hydrogen bonds. The intermolecular hydrogen
bonds are indicated by blue dotted lines.
EGCgINA:

It is possible to generate a stable anhydrous form of the

EGCgINA•3H2O cocrystal by heating to 85°C.

The water loss can be

confirmed by comparing the differential scanning calorimetry data before
and after heating (Figure 5.5).
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Figure 5.5
Differential scanning calorimetry data of EGCgINA and EGCgINA•3H2O. The
first dip in the green line is indicative of water loss for the hydrate. The first dip is
nonexistent in the red line because water is not present in this cocrystal.
5.3.2 Solubility of the EGCg cocrystals
EGCg is considered to have good aqueous solubility (approximately 20 mg/ml).
We determined the solubility profiles of four new EGCg cocrystals. All of the
cocrystals exhibited reduced water solubility. Figure 5.6 shows the dissolution
profiles of EGCg and the EGCg cocrystals. The maximum solubility of EGCg
determined

experimentally

approximately 22 mg/ml.

was

in

agreement

with

published

values,

The EGCG cocrystals exhibited far lower aqueous

solubility. This is apparent in Figures 5.6 and 5.7. The most soluble cocrystal
was EGCgNIC•9H2O at 2.95±0.11 mg/ml.

This was followed by EGCgINA,

EGCgINM•5H2O, and EGCgINA•3H2O at 1.227±0.036, 1.401±0.122, 0.97±0.07,
respectively.
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Figure 5.6
Dissolution profiles of EGCg and EGCg cocrystals in water.

Figure 5.7
Dissolution profiles of EGCg cocrystals alone in water.
5.3.3 Pharmacokinetics of EGCg cocrystals
The pharmacokinetic curves for EGCg and the EGCg cocrystals are shown in
figure 5.8. EGCg exhibited the prototypical pharmacokinetic curve for a highly
water-soluble small molecule: rapid peak and elimination. The EGCg cocrystals
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exhibited very different pharmacokinetic profiles.

The pharmacokinetic

parameters are shown in Table 5.1. EGCg peaked rapidly at 5 minutes (Tmax)
due to its high solubility and, consequent, high rate of dissolution. The cocrystals
peaked in the plasma in the following order: EGCgNIC•9H2O, EGCgINM•5H2O,
EGCgINA•3H2O, EGCgINA.

Surprisingly, only two of the cocrystal forms

resulted in improved bioavailability: EGCgINA•3H2O and EGCgINA.

These

cocrystals had modest improvements in relative bioavailability at FREL of 1.53 and
1.18, respectively.

Free EGCg peaked at higher concentrations and more

quickly than the cocrystal forms.
overall

shape

of

the

However, cocrystallization did change the

pharmacokinetic

curve.

In

some

cases,

these

pharmacokinetic profiles might be advantageous to the typical peak and
elimination profile of free EGCg.

Figure 5.8
Pharmacokinetic profiles of EGCg and EGCg cocrystals.
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Table 5.1. Pharmacokinetic parameters
TMAX
(min)
CMAX
(ng/ml)
AUC
FREL
A T1/2
(min)

EGCg

EGCgNIC•9H2O

EGCgINM•5H2O

EGCgINA•3H2O

EGCgINA

5.0

10.0

30.0

60.0

120.0

337.2

185.8

126.0

297.9

149.6

35602.0
1.00

25237.0
0.71

22707.0
0.64

54560.0
1.53

41937.0
1.18

1.64

3.75

10.44

30.53

62.71

5.4 Discussion and conclusions
Tea is the most widely consumed beverage in the world. One of the most
popular types of tea is green tea.

Green tea contains numerous bioactive

ingredients but the most beneficial class of compounds is thought to be the
polyphenols. Of the polyphenols found in green tea, EGCg is the most abundant.
EGCg

research

increased

drastically

when

researchers

reported

that

epidemiological evidence indicated lower rates of certain cancers in populations
that consumed the most green tea.

Since then, numerous molecular

mechanisms for these beneficial properties have been discovered.

Not

surprisingly, EGCg has become one of the most popular nutraceutical ingredients
in the world.

However, reports of its poor bioavailability are troublesome to

product development (Landis-Piwowar, Huo et al. 2007; Dube, Nicolazzo et al.
2010; Kale, Gawande et al. 2010; Smith, Giunta et al. 2010). EGCg is highly
susceptible to oxidation, first pass metabolism and rapid efflux (Kale, Gawande
et al. 2010). Numerous groups have evaluated delivery systems to overcome
these limitations but none have tried cocrystallization.
In this study, we report four new cocrystals of EGCg all with reduced water
solubility. We hypothesized that these changes in solubility would change the
pharmacokinetics of EGCg, perhaps improving it’s bioavailability. At first glance,
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it seems that cocrystallization might not be the most useful method for improving
the bioavailability of EGCg, since only two cocrystals exhibited improved
bioavailability and the increases were very modest (Table 5.1). However, that
does not mean that cocrystallization cannot benefit the commercialization of
EGCg.

The ability to have multiple solid forms of EGCg with different

physicochemical properties and pharmacokinetic profiles could be very useful.
Further examination of Figure 5.8 indicates that some of the EGCg cocrystals
exhibited very unique pharmacokinetic profiles.

The EGCgINA•3H2O and

EGCgINA cocrystals not only had the highest relative bioavailabilities, but also
resulted in higher concentrations of free EGCg after 60 and 120 minutes. This
plateau effect could be useful for achieving more sustained levels of EGCg in the
blood. Additionally, because nutraceutical products often contain combinations
of ingredients with synergistic effects, cocrystallization could be used to select
forms with similar pharmacokinetic curves as the other ingredients, thus,
optimizing the synergisms.
Our results generally had the hypothesized effect: reducing the solubility
reduced the rate of dissolution and delayed the time at which maximal plasma
levels were reached (Tmax).

EGCgNIC•9H2O was the most water-soluble

cocrystal form and had the most rapid Tmax after free EGCg. EGCgINM•5H2O
and EGCgINA•3H2O had expected Tmax values as well. However, EGCgINA
peaked last at 120 minutes (Table 5.1) and was the second most soluble
cocrystal (Figure 5.7). This phenomenon cannot be explained by our solubility
hypothesis.
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pharmacokinetic parameters are being changed, like elimination rate or
metabolism. However, this would normally be attributed to some effect of the
cocrystal former.

This theory is debunked in our experiment because we

evaluated EGCgINA and EGCgINA•3H2O. As expected, the hydrate exhibited
lower water solubility and peaked later in comparison to the other more soluble
EGCg forms. Because anhydrous and hydrous forms were evaluated, we are
able to conclude that the presence of isonicotinic acid does not explain the
discrepancy observed with the EGCgINA cocrystal. This phenomenon could be
due to experimental error since this was a relatively low n study.
In conclusion, cocrystallization might not be the best option for improving
the bioavailability of highly water-soluble cocrystals. However, it could be very
useful when absorption kinetics is critical such as it is in synergistic combination
products.

Additionally, cocrystallization is capable of broadening intellectual

property since the only requirement for cocrystal formation is complementary
functional groups. This is unlike salts, which require the presence of ionizable
species severely limiting the number of possibilities and, in many cases,
rendering the potential for salt formation impossible for certain compounds. This
study is good proof of principle for the use of cocrystallization to modulate the
pharmacokinetics of highly water-soluble compounds.

In this study, we

described the creation of four new solid forms of EGCg, each with unique
physicochemical properties and pharmacokinetic characteristics.
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CHAPTER 6
DISCUSSION

6.1 Nanolipidic flavonoid complexes
Nanoparticles have been long studied as a means of preformulation for
improving the oral bioavailability of various compounds.

Most often, the

compounds selected for nanoparticle preformulations exhibit low water solubility
and, thus, dissolve slowly or incompletely thwarting their absorption and
bioavailability.

These compounds generally fall under the Biopharmaceutics

Classification System (BCS) as Class II active pharmaceutical ingredients
because they present low solubility and high permeability.

BCS Class II

compounds are generally limited by their rate of dissolution, which slows their
absorption.

Recently, one group has utilized solid lipid nanoparticles to

drastically improve the bioavailability of another natural compound, curcumin
(Kakkar, Singh et al. 2011).

Curcumin has very poor bioavailability due to

inadequate water solubility. Kakkar et al reported increases in oral bioavailability
of up to 155 times, dependent on the dose administered.
Nanolipidic particles have been reported to increase the absorption of
compounds via the lymphatic system (Porter, Trevaskis et al. 2007). Lymphatic
drug absorption requires a compound to be highly lipophilic or to be complexed
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to a lipidic material as is the case with nanolipidic particles.

Lymphatic

absorption offers the advantage of bypassing first pass metabolism, resulting in
elevated systemic circulation levels of the free xenobiotic.

These were key

factors that contributed to our development of EGCg nanolipidic particles and
provided rationale for our pharmacokinetic studies.

We evaluated the

pharmacokinetics of nanolipidic EGCg particles using Sprague dawley rats. We
administered the “free” EGCg in the same vehicle that was used in the
NanoEGCg formulation minus the lipid carrier. What we found was that EGCg
was absorbed very poorly, peaking at 116 ng/ml. In comparison, the NanoEGCg
formulations exhibited more than double the relative bioavailability. Given that
lipidic formulations have been shown to increase lymphatic absorption (Peng,
Zhang et al. 2010), it is possible that this is one mechanism for the improved
bioavailability of NanoEGCg. Additionally, EGCg has been shown to be highly
susceptible to metabolism in the gastrointestinal tract pre-absorption (Takagaki
and Nanjo 2010), thus, it is possible that the NanoEGCg is less susceptible
metabolism by intestinal flora.

Unfortunately, one major limitation to this

technology is that it requires ethanol for nanoparticle formation. This is not ideal
for the commercialization of EGCg as a dietary supplement or as a drug. Not
only this, but the ethanol content alone probably effected the absorption of
EGCg. This is evidenced by the fact that the plasma levels reached by our
EGCg control were lower than previously reported (Lin, Wang et al. 2007). This
limitation must be considered when interpreting the results but does not change
the fact that the systemic absorption of free EGCg in the nanoEGCg formulation
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was vastly superior to the control. Alternative methods for nanoEGCg production
without alcohol should be explored in future studies.
6.2 Solid-state chemistry
The fact that the majority of drugs are marketed and sold as solid dosage
forms is a testament to the importance of solid-state chemistry in the
pharmaceutical industry. They have important implications in clinical, legal, and
even regulatory perspectives. Perhaps the most pertinent factor contributing to
the emphasis being placed on solid-state chemistry is the fact that novel solid
forms offer a way to change the physicochemical characteristics of compounds
with less than desirable properties in their pure form. One of the most rapidly
emerging new solid forms are cocrystals. Shan and Zaworotko have defined
cocrystals as “multiple component crystals in which all components are solid
under ambient conditions. These components co-exist as a stoichiometric ratio
of a target molecule or ion and a neutral molecular cocrystal former(s)” (Shan
and Zaworotko 2008). Cocrystals are particularly useful because they involve
noncovalent hydrogen bonds, which pose fewer limitations than covalent
modifications and ionic complexes (salts). Because cocrystals can be formed
from compounds without ionizable species, the number of possible combinations
are staggering in comparison to other solid forms.
Recent advances in crystal engineering have propelled cocrystallization to
the forefront of solid-state chemistry. Now, supramolecular heterosynthons that
seem to favor the formation of cocrystals have been discovered. Those relevant
to the studies discussed in chapters 4 and 5 are exemplified by carboxylic acid-
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aromatic nitrogen, carboxylic acid-amide, and alcohol-pyridine (Shan and
Zaworotko 2008). This supramolecular synthon approach was employed in the
development of all of the cocrystals evaluated in this report. This took much of
the trial and error out of cocrystal development and allowed for effective selection
of cocrystal formers that were most likely to hydrogen bond with the
bioflavonoids: EGCg and quercetin. Furthermore, these synthons can be applied
to other structurally similar bioflavonoids.

The studies described in previous

chapters of this report attest to the effectiveness of this crystal engineering
approach.
6.2.1 Pharmacokinetic implications of cocrystals of quercetin
Quercetin

was

chosen

as

one

of

the

bioflavonoids

for

these

cocrystallization studies because it exhibits extremely low water solubility, a very
common problem in drug development. Quercetin’s water solubility of 0.00215
mg/mL (Srinivas, King et al. 2010) is the major contributor to it’s poor
bioavailability. For a compound to be absorbed by the body it must dissolve,
which is dependent on it’s solubility in aqueous mediums. Our hypothesis was
that we could improve the solubility of quercetin by forming new cocrystal forms.
In turn, this would produce predictable changes in the pharmacokinetic profiles
leading to improvements in the bioavailability.
Our results supported this hypothesis in a broad sense. Each of the four
cocrystals exhibited marked improvements in solubility. However, our ability to
evaluate the changes in pharmacokinetics that could be produced by small
differences in aqueous solubility was limited because we were forced to use a
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50% ethanol medium to produce quantifiable levels of quercetin for the quercetin
dihydrate control. Although this makes it difficult to make accurate conclusions
that are physiologically relevant, it is very obvious that the cocrystals exhibited
increased solubility and improved bioavailability. Additionally, we would expect
that increasing the solubility would increase the rate of dissolution and cause the
plasma levels to peak earlier. This was the case for all of the quercetin cocrystal
formulations. The quercetin dihydrate control was absorbed slowly (Tmax at 30
minutes) and poorly (Cmax at 285 ng/mL).

In comparison, the quercetin

cocrystals reached peak levels at 5 and 10 minutes.

The QUECAF•MeOH

peaked the highest at 2612 ng/mL followed by QUEINM at 1401 ng/mL,
QUETBR•2H2O at 840 ng/mL, and QUECAF at 656 ng/mL. This increases in
absorption resulted in increases in bioavailability of up to nearly 10 fold. The
lowest performing cocrystal in terms of bioavailability was QUECAF, which still
produced increases in relative bioavailability of 2.57 fold. The cocrystals were
absorbed similarly and there was little meaningful difference in the absorption
half lives. However, the elimination half lives were indicative of major changes in
the pharmacokinetics of the cocrystals. This was unexpected. We anticipated
that we would change the rate of dissolution, improving the absorptive phase of
the cocrystals. However, it appears that cocrystallization also produces profound
effects on the elimination phase. This was most evident for QUETBR•2H2O that
exhibited an elimination half life of 145 minutes.

This parameter can be

visualized by looking the shape of the pharmacokinetic curve (Figure 4.4). The
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shape is not a peak with rapid elimination, but a peak with a plateau effect. This
is what produced huge gains in bioavailability (FREL=9.93).
The impact of these studies is two fold. It provides more evidence that
poorly soluble compounds can be improved drastically using cocrystallization
(Hickey, Peterson et al. 2007; Bak, Gore et al. 2008; Jung, Kim et al. 2010).
Also, it could help commercialize quercetin as a dietary supplement and
eventually as a therapeutic agent. QUE is best known for its antioxidant activity
but has numerous other biological and pharmacological effects including metal
chelation, anti-carcinogenic, cardioprotective, bacteriostatic, and antiviral activity
(Vargas and Burd ; Bakay, Mucsi et al. 1968; Formica and Regelson 1995;
Spencer, Kuhnle et al. 2003; Leopoldini, Russo et al. 2006; Murakami, Ashida et
al. 2008).

However, these bioactivites are meaningless unless it’s poor

absorption and bioavailability can be overcome. Our studies offer four quercetin
cocrystals that accomplish this. Future studies will need to assess the translation
of these results into humans.
6.2.2 Pharmacokinetic implications of cocrystals of EGCg
EGCg was selected for this study to represent the opposite end of the
solubility spectrum. EGCg is a highly water-soluble compound. We used the
supramolecular heterosynthon approach to identify cocrystal formers with
complementary functional groups to form hydrogen bonds with the hydroxyl
groups abundant on EGCg.

This crystal engineering approach to cocrystal

design was very effective and we generated several new EGCg cocrystals. The
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four presented in this study were selected to advance to the in vivo
pharmacokinetic studies.
EGCg usually exhibits a prototypical pharmacokinetic profile for highly
water soluble compounds: it peaks rapidly and is eliminated rapidly from
systemic circulation via tissue distribution and metabolism at the liver.

We

hypothesized that cocrystals with reduced solubility would change the dissolution
and consequent absorption of the compound in the gastrointestinal tract. This
hypothesis was mostly supported by our results.
We evaluated four new cocrystal forms of EGCg in a rat model of
pharmacokinetics and bioavailability. The EGCg formulations were administered
in vegetable oil to prevent presolubilization of the powder forms. Sieving the
powders prior to slurrying in vegetable oil and dosing the animals via oral gavage
regulated the particle size. The EGCg control was absorbed rapidly absorbed
(TMAX=5 minutes) and eliminated quickly.

The EGCg cocrystals exhibited a

delayed absorption pattern that coincided with the decreases in solubility in all
cases except one: EGCgINA. This cocrystal was the second most soluble but
appeared in the plasma last. We can only attribute this to experimental error
since there is no other explanation for it.

That aside, our hypothesis was

supported by our results. Interestingly, oral bioavailability was not improved from
EGCg alone except very modestly with the EGCgINA•3H2O and EGCgINA
cocrystals. These cocrystals had the latest TMAX values.
Although, at first glance, it might be easy to conclude that cocrystallization
is not useful for improving the bioavailability of highly water-soluble compounds
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this might not be true. In this study, we generated four new cocrystal forms of
EGCg with different physicochemical and pharmacokinetic properties. During
commercialization, it is possible to formulate the EGCg cocrystals into a
combination product.

This, in theory, has the potential to create sustained

plasma levels of free EGCg. This possibility was simulated in Figure 6.1.

Figure 6.1
Pharmacokinetic curve of theoretical combination delivery of all cocrystal forms
simultaneously (25 mg/kg each).
Figure 6.1 was generated by combining the experimental pharmacokinetic curves
of all of the cocrystals divided by 4 (to adjust the dose to 100 mg/kg total of
EGCg). In theory, this is the pharmacokinetic curve that would occur if all of the
cocrystal forms were dosed into an animal at once. As shown in Figure 6.1, this
would cause the pharmacokinetic curve to plateau similar to other sustained
release preformulation techniques like transdermal delivery. Sustained plasma
levels are preferred so that the therapeutic bioactivity of the active ingredient is
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maintained for a longer duration. Even though transdermal delivery can also
accomplish sustained plasma levels, it has numerous disadvantages to oral
formulation such as complicated production, increased cost, and reduced patient
compliance due to common side effects like skin irritation at the adhesion site.
A single cocrystal with reduced solubility from the pure form of a highly
water-soluble compound is unlikely to produce improved bioavailability.
However, the ability to modulate the pharmacokinetic curve could be very useful
in the clinical translation of active ingredients. The opportunities are there to
create combination products that produce sustained plasma levels of a single
active ingredient.
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APPENDIX 1:
ADDITIONAL QUERCETIN COCRYSTAL FIGURES
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Figure A1.1
QUECAF•MeOH (Methanol solvate of 1:1 cocrystal Quercetin and Caffeine)
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QUEINM (1:1 cocrystal of Quercetin and Isonicotinamide)
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APPENDIX 2:
DATA SHEET FOR EGCGNIC•9H2O: HYDRATE OF 1:1 COCRYSTAL OF
EPIGALLOCATECHIN GALLATE (EGCG) AND NICOTINAMIDE
Description:
The single crystal x-ray structure analysis reveals that EGCGNIC•9H2O is a
decahydrate of 2:2 co-crystal of EGCG and nicotinamide.
Figure A2.1: FT-IR of EGCGNIC•9H2O. (Nicolet Avatar 320 FTIR, solid state)
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Figure A2.2: DSC of EGCGNIC•9H2O (TA instrument 2920)
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Figure A2.3: Powder x-ray diffraction patterns of EGCGNIC•9H2O
Calculated (top) and Experimental (bottom)
(Bruker AXS D8, Cu radiation)

Major peaks were observed in the experimental PXRD pattern at the following
positions: 8.8, 11.9, 13.3, 15.8, 17.2, 18.4, 19.3, 20.3, 21.2, 23.5, 24.2, 25.1,
26.1, 27.7, 28.8, 29.7, 33.0 and 34.4 degrees.
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Figure A2.4: Comparison of powder x-ray diffraction patterns of
EGCGNIC•9H2O.
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Major peaks were observed in the experimental PXRD pattern at the following
positions: 8.8, 11.9, 13.3, 15.8, 17.2, 18.4, 19.3, 20.3, 21.2, 23.5, 24.2, 25.1,
26.1, 27.7, 28.8, 29.7, 33.0 and 34.4 degrees.
Figure A2.5: TGA analysis of EGCGNIC•9H2O
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Table A2.1: Single crystal x-ray diffraction data for EGCGNIC•9H2O
(Bruker-AXS SMART APEX CCD diffractometer)

Crystallographic data
Identification code
Empirical formula
Formula weight
Temperature
Wavelength
Crystal system
Space group
Unit cell dimensions

Volume
Z
Density (calculated)
Absorption coefficient

EGCgNIC•9H2O
2(C22 H18 O11) · 2(C6 H6 N2 O) · 10(O)
660.49
100(2) K
1.54178 Å
Triclinic
P1
a = 10.497(2) Å
a= 72.56(3)°.
b = 11.769(2) Å
b= 85.80(3)°.
c = 12.203(2) Å
g = 83.00(3)°.
3
1426.4(5) Å
2
1.538 Mg/m3
1.128 mm-1

Independent reflections
Final R indices [I>2sigma(I)]
R indices (all data)

7923 [R(int) = 0.0411]
R1 = 0.0700, wR2 = 0.1904
R1 = 0.0832, wR2 = 0.2045
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Figure A2.6: Digital microscope image of EGCGNIC•9H2O crystals

Figure A2.7: Intermolecular hydrogen bonding in EGCGNIC•9H2O
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APPENDIX 3:
DATA SHEET FOR EGCGINM•5H2O: HYDRATE OF 1:1 COCRYSTAL OF
EPIGALLOCATECHIN GALLATE (EGCG) AND ISO-NICOTINAMIDE
Description:
The single crystal x-ray structure analysis reveals that EGCGINM•5H2O is a
hydrate of 1:1 cocrystal of EGCG and iso-nicotinamide. EGCG molecules and
iso-nicotinamide molecules interact through one point hydrogen bonds (OH···N, O···N: 2.756Å) between the hydroxyl group of EgCG molecule and the
aromatic nitrogen of iso-nicotinamide molecules. These dimeric units are
further connected by O-H···O (O···O: 2.662Å) hydrogen bonds formed between
hydroxyl moieties of EgCG and carbonyl moieties of iso-nicotinamide
molecules and thereby form zig-zag chains.
Figure A3.1: FT-IR of EGCGINM•5H2O (Nicolet Avatar 320 FTIR, solid state)
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Figure A3.2: DSC of EGCGINM•5H2O (TA instrument 2920)
Sample: ka10153_1
Size: 6.0000 mg
Method: Ramp

File: C:...\kapil\ka10153_1.001
Operator: kapil
Run Date: 3-Mar-08 15:50
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Figure A3.3: Calculated (top) and experimental (bottom) powder x-ray
diffraction patterns of EGCGINM•5H2O (Bruker AXS D8, Cu radiation)

Major peaks were observed in the experimental powder x-ray diffraction
pattern at about the following positions: 7.6, 8.5, 9.2, 11.5, 12.6, 15.4, 18.7,
19.1, 20.0, 24.7, 26.4, 27.7 and 35.2 degrees.

	
  

107	
   	
  

Figure A3.4: Comparison of experimental and calculated powder x-ray
diffraction patterns of EGCGINM•5H2O
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Table A3.1: Single crystal x-ray diffraction data for EGCGINM•5H2O
(Bruker-AXS SMART APEX CCD diffractometer)

Crystallographic data
Empirical formula
Formula weight
Temperature
Wavelength
Crystal system
Space group
Unit cell dimensions

Volume
Z
Density (calculated)
Absorption coefficient
Independent reflections
Final R indices [I>2sigma(I)]
R indices (all data)

	
  

C28 H24 N2 O17
660.49
298(2) K
0.71073 Å
Monoclinic
C2
a = 19.603(8) Å
b = 14.491(6) Å
c = 10.585(4) Å
3005(2) Å3
4
1.460 Mg/m3
0.124 mm-1

a= 90°.
b= 92.089(7)°.
g = 90°.

4761 [R(int) = 0.0238]
R1 = 0.0671, wR2 = 0.1782
R1 = 0.0964, wR2 = 0.2235
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Figure A3.5: Digital microscope image of EGCGINM•5H2O crystals

Figure A3.6: Intermolecular hydrogen bonding in EGCGINM•5H2O

Figure A3.7: An EGCG molecule as it exists in EGCGINM•5H2O
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APPENDIX 4:
DATA SHEET FOR EGCGINA•3H2O: HYDRATE OF 1:1 COCRYSTAL OF
EPIGALLOCATECHIN GALLATE (EGCG) AND ISONICOTINIC ACID AND
EGCGINA: ANHYDRATE OF 1:1 COCRYSTAL OF EPIGALLOCATECHIN
GALLATE (EGCG) AND ISONICOTINIC ACID
Description:
The single crystal x-ray structure analysis reveals that EGCGINA•3H2O is a
trihydrate of 1:1 co-crystal of EGCG and nicotinamide.
Figure A4.1: FT-IR of EGCgINA. (Nicolet Avatar 320 FTIR, solid state)
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Figure A4.2: DSC of EGCGINA•3H2O and EGCgINA (TA instrument 2920)

Green = EGCG:Isonicotinic acid trihydrate = EGCGINA•3H2O
Red = EGCG:Isonicotinic acid anhydrate = EGCgINA
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Figure A4.3: Powder x-ray diffraction patterns of EGCGINA•3H2O
Calculated (top) and Experimental (bottom)
(Bruker AXS D8, Cu radiation)

Major peaks were observed in the experimental PXRD pattern at the following
positions: 12.3, 13.8, 15.2, 18.3, 18.8, 20.6, 21.5, 24.2, 24.8, 25.5, 26.5, 27.6,
28.1, 29.0, 30.6, 31.5, 32.7, 35.6 and 38.4 degrees.
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Figure A4.4: Comparison of powder x-ray diffraction patterns of
EGCGINA•3H2O.

Major peaks were observed in the experimental PXRD pattern at the following
positions: 12.3, 13.8, 15.2, 18.3, 18.8, 20.6, 21.5, 24.2, 24.8, 25.5, 26.5, 27.6,
28.1, 29.0, 30.6, 31.5, 32.7, 35.6 and 38.4 degrees.
Figure A4.5: Experimental powder x-ray diffraction patterns of EGCgINA
(Bruker AXS D8, Cu radiation)

Major peaks were observed in the experimental PXRD pattern at the following
positions: 6.9, 13.7, 14.5, 17.3, 18.4, 19.3, 20.5, 23.8, 24.7, 27.3, 28.1, 29.9,
30.6, 34.3, 36.5 and 38.3 degrees.
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Figure A4.6: Comparison of powder x-ray diffraction patterns of
EGCGINA•3H2O and EGCgINA.

Major peaks were observed in the experimental PXRD pattern of EGCgINA at
the following positions: 6.9, 13.7, 14.5, 17.3, 18.4, 19.3, 20.5, 23.8, 24.7, 27.3,
28.1, 29.9, 30.6, 34.3, 36.5 and 38.3 degrees.
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Figure A4.7: Comparison of powder x-ray diffraction patterns of EGCgINA,
EGCG form-1 and isonicotinic acid
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Major peaks were observed in the experimental PXRD pattern of EGCgINA at
the following positions: 6.9, 13.7, 14.5, 17.3, 18.4, 19.3, 20.5, 23.8, 24.7, 27.3,
28.1, 29.9, 30.6, 34.3, 36.5 and 38.3 degrees.
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Figure A4.8: TGA analysis of EGCGINA•3H2O

Calculated = 8.5% weight loss for 3 water molecules
Experimental = 6.9% weight loss
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Table A4.1: Single crystal x-ray diffraction data for EGCGINA•3H2O
(Bruker-AXS SMART APEX CCD diffractometer)

Crystallographic data
Identification code
Empirical formula
Formula weight
Temperature
Wavelength
Crystal system
Space group
Unit cell dimensions

	
  

Volume
Z
Density (calculated)
Absorption coefficient

EGCgINA•3H2O
C22 H18 O11:C6H5NO2:3O
547.88
100(2) K
1.54178 Å
Orthorhombic
P212121
a = 7.5176(7) Å
a= 90°.
b = 14.0259(11) Å
b= 90°.
c = 26.174(2) Å
g = 90°.
2759.9(4) Å3
4
1.319 Mg/m3
0.940 mm-1

Independent reflections
Final R indices [I>2sigma(I)]
R indices (all data)

4298 [R(int) = 0.0517]
R1 = 0.1099, wR2 = 0.2850
R1 = 0.1255, wR2 = 0.2959
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Table A4.2: Single crystal x-ray diffraction data for EGCgINA – unit cell
parameters
(Bruker-AXS SMART APEX CCD diffractometer)
Crystallographic data
Identification code
Empirical formula
Formula weight
Temperature
Wavelength
Crystal system
Space group
Unit cell dimensions

Volume

	
  

EGCgINA
C22 H18 O11:C6H5NO2
547.88
100(2) K
1.54178 Å
Orthorhombic
P212121
a = 7.3367(22) Å
b = 13.1192(39) Å
c = 25.9406(77) Å
2496.83 Å3
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a= 90°.
b= 90°.
g = 90°.

Figure A4.9: Intermolecular hydrogen bonding in EGCGINA•3H2O
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